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Abstract 
In the past few years, interest in signaling networks involving 3ʹ, 5ʹ -cyclic diguanylic acid (c-di-
GMP) has increased dramatically. Evidence started to emerge that connects c-di-GMP to the 
regulation of a range of biological processes in bacteria, such as bacterial biofilm formation, 
virulence, extracellular polysaccharide synthesis, however, much remains to be explored in the 
signaling pathways that involve this secondary messenger. This molecule has also been shown to 
be a very powerful immunostimulating agent and potent mucosal vaccine adjuvant.  
Research in our lab has been directed towards the understanding of the structure – activity 
relationship of c-di-GMP, particularly the relevance of base residues in the bioactivity of 
corresponding c-di-GMP analogues. Towards this goal, the cytidine analogue of c-di-GMP, i.e. c-
di-CMP, was successfully synthesized via the modified H-phosphonate approach. In this 
synthesis, the 2’-hydroxyl group were protected by the 1-(4-chlorophenyl)-4-ethoxy-1,2,5,6-
tetrahydropyridine (Cpep) group. The activity of c-di-CMP in regulating bacterial biofilm 
formation and its immunostimulating properties are currently under evaluation. Towards the 
investigation of cellular and tissue distributions of c-di-GMP, and potentially identify c-di-GMP 
binding proteins, attempts were made towards the synthesis of guanosine bearing 2’-O-(6-
azidohexyl) modification using 2,6-diaminopurine ribonucleoside as starting material. In this 
work, the synthesis of N
2
-isobutyryl-3’,5’-(1,1-dichloro-1,1,3,3-tetraisopropyldisiloxan-3’,5’-
diyl)-2’-O-(6-hydroxyhexyl)guanosine was accomplished. Future work will focus on the 
synthesis of 2’-O-modified c-di-GMP using this building block.   
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Chapter 1 
1.1 Introduction to c-di-GMP 
Research in cyclic bis-(3ʹ,5ʹ)diguanylic acid (c-di-GMP) began in the early 1980s in the 
laboratory of Moshe Benziman at the Department of Biological Chemistry of the Hebrew 
University of Jerusalem, Israel. The discovery of this new nucleotide in 1987 was a result of 
many years of research on the enzymatic mechanism and regulation of cellulose biosynthesis 
in the gram-negative bacterium Gluconacetobacter xylinus (formerly Acetobacter xylinum)  
by Benziman and co-workers.
1-3 
In the subsequent years and until his death in 2003, 
Benziman and his coworkers published several papers describing various aspects of c-di-
GMP biochemistry
4, 5
 and finally identifying the enzymes responsible for c-di-GMP synthesis 
and hydrolysis.
6
 Some details of the history of the c-di-GMP discovery can be found in the 
1991 review written by Benziman and his graduate students Peter Ross and Raphael Mayer.
3 
 
C-di-GMP is an important molecule with a role in intracellular signaling in many 
different kinds of bacteria. Bacteria use the signal transduction mechanisms to respond to 
various environmental changes, such as temperature, pH, and concentration of oxygen. In this 
role, c-di-GMP has been recognized as an important bacterial second messenger that relays 
signals from receptors on the cell surface to target molecules inside the cell, in the cytoplasm 
or nucleus.  
There are some other second messengers that were previously identified such as, 
cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP) and 
guanosine tetra- and pentaphosphate((p)ppGpp) (Figure 1-1), all these second messengers 
participate in biological signal transduction pathways. 
 
2 
 
 
                 Figure 1-1 Structures of known nucleotide-based second messengers.  
In the early 2000s, research emerged that connected c-di-GMP signaling to proteins that 
contain the GGDEF (Gly-Gly-Asp-Glu-Phe) domain, the EAL (Glu-Ala-Leu) domain, or 
both. The EAL domain contains approximately 240 amino acids that fold into a globular 
structure.The domain name originates from one of the most conserved amino acid signature 
motif. Like GGDEF, EAL is usually found as part of multidomain signaling proteins in 
combination with periplasmic membrane-embedded or cytoplasmic ligand binding sensory 
domains. Approximately half of all EAL domains are associated with GGDEF domains.
7
 It is 
also important to note that although the Glu-Ala-Leu sequence motif appears to play a role in 
the c-di-GMP specific phosphodiesterase activity of the EAL domain, the presence of this 
motif in a given protein does not mean that the protein would have phosphodiesterase 
activities.
8
 The identification of the GGDEF domain as a component of diguanylate cyclase 
(DGC) was a turning point for c-di-GMP research in at least two aspects.
 6
 First it provided 
3 
 
the first evidence of an enzymatic function for this widespread protein domain and paved the 
way to the experimental demonstration that the GGDEF domain alone was responsible for the 
DGC activity.
9, 10
 Second, the link between this widespread domain and c-di-GMP turnover 
provided evidence for the participation of c-di-GMP in a variety of signaling processes.
11,12
 
          C-di-GMP can be synthesized by DGC 
11   
from two molecules of guanosine 
triphosphate (GTP) through a linear intermediate pppGpG. DGC enzymes are found to 
contain the conserved GGDEF domain. On the other hand, c-di-GMP is degraded by 
phosphodiesterases (PDE) to guanosine monophosphate (GMP).   
C-di-GMP is an allosteric regulator of downstream proteins. Upon binding to c-di-
GMP, the proteins undergoes conformational changes, and provide positive or negative 
regulation on some biological functions. These signal transduction pathways enable bacteria 
to respond to environmental cues and survive in challenging environments. It has been found 
that most GGDEF and EAL (or HY-GYP) domains are associated with cytoplasmic signaling 
domains, such as PAS (oxygen sensing). The PAS domain is assumed to have a binding 
pocket for heme
13
 or flavin,
14  
which can act as an oxygen or redox potential sensing domain. 
In biosynthesis of cellulose in G. xylinus, for example, oxygen is the first messenger that 
binds to the PAS domain. Depending on the level of oxygen in the environment, c-di-GMP 
provides a mechanism to regulate cellulose synthesis through the modulation of the activity 
of cellulose synthase in G. xylinus. In this bacterium, the PDE activity that is executed 
through EAL domain depends on the binding status of PAS domain towards oxygen, which 
serves as the first messenger. When the environmental concentration of oxygen is high, the 
PDE activity decreases due to the binding of PAS domain to Oxygen. Consequently, cellulose 
synthase is activated to produce cellulose (Figure 1-2 (b)) as a result of accumulation of 
cellular c-di-GMP. When the oxygen level is low in the environment, however, 
4 
 
phosphodiesterase activity is restored, leading to decrease in the concentration of c-di-GMP 
and thus inactivation of cellulose synthase (Figure 1-2(a)).
13
 
 
 
 
Figure1-2 C-di-GMP regulation of cellulose synthesis in G. xylinus.
15 
(Reprinted from the 
Chemical Society Review) 
 
1.2 Structural investigation of c-di-GMP 
The structure of c-di-GMP was determined by nuclear magnetic resonance (NMR)
16
 and X-
ray crystallography.
17-20
 In all these structures, the 12-member macrocycle formed by the 
ribose and phosphate moieties is found to maintain virtually the same conformation.
21
 This 
homodimeric form of c-di-GMP has a dramatically different molecular outline from the 
5 
 
monomer which means that the monomeric versus dimeric forms are likely to interact with 
different receptors (Figure 1-3).
 
In the dimeric form, association of c-di-GMP with Mg
2+
 or 
Co
2+
 is observed in some structures, where these cations are found on the two fold symmetry 
axis coordinated by the N-7 atoms of the two central bases, but their presence does not 
significantly change the structure of the dimer.
18-20 
 
(A)  (B) 
 
Figure 1-3 (A) Top view of c-di-GMP in the monomer form; (B) c-di-GMP in the dimer 
form, with hydrogen bonds shown as dash lines.
15
 (Reprinted from the Chemical Society 
Review). 
 
 
It was also shown that in solution, equilibrium of dimeric, tetrameric and octomeric c-di-
GMP can be affected by both c-di-GMP concentration and presence of metal ions. In this 
respect, in lower concentrations of c-di-GMP and the presence of small metal ions such as 
Li
+
, the equilibrium prefers the formation of bimolecular structures. However, in higher 
concentrations and presence of larger metal ions, such as K
+
, the equilibrium prefers the 
formation of more complex assembly (Figure 1-4).
22  
6 
 
 
Figure 1-4 Cartoon of c-di-GMP intermolecular assembly.
22
 (Reprinted from the American 
Chemical Society). 
 
The biological significance of this equilibrium is not clear, however, it was 
hypothesized that dimeric c-di-GMP can provide a feed-back inhibition for the DGC domain 
in Gaulobacter crescentus. In this bacterium the PleD protein consists of a receiver domain 
(D1), adapter domain (D2) and also a DGC domain. When D1 is phosphorylated, PleD is 
activated at the differentiating pole, which catalyzes the conversion of two molecules of GTP 
to c-di-GMP (Figure1-5). It has been proposed that the c-di-GMP dimer can bind to the 
D2/DGC domain (inhibition site or I-site),
23 
leading to inactivation of the DGC enzyme. This 
feedback regulation of PleD by product inhibition shows the importance of an upper limit on 
the concentration of c-di-GMP.   
 
7 
 
 
Figure 1-5 PleD regulation of c-di-GMP synthesis in vivo.
23
 
(Reprinted from the Proceeding of National Academy of Science. USA) 
 
1.3 Immunostimulatory properties of c-di-GMP 
C-di-GMP recently gained significant attention among immunologists due to its extraordinary 
immunostimulatory and immunomodulatory properties. In the initial experiments, c-di-GMP 
was shown to induce the activation and maturation of human immature dendritic cells (DCs), 
the professional antigen-presenting cells, in vitro.
24
 The activation of DCs was proved by the 
increased levels of key chemokines and cytokines upon treatment of DC cultures with c-di-
GMP.  
Further, intranasal treatment of mice with c-di-GMP increases the level of cytokines and 
chemokines in Bronchoalveolar lavage (BAL) that are essential in the recruitment of 
neutrophils such as IL-8, KC, RANTES, IL-6, MIP-2, MCP-1 (Top panel, Figure 1-10). On 
the other hand, the level of these cytokines and chemokines normalized seven days after the 
8 
 
treatment (Bottom panel, Figure 1-6). These data strongly suggested the immunostimulatory 
properties of c-di-GMP at a mucosal site.
25
 
 
 
Figure 1-6 Proinflammatory cytokine/chemokine levels in bronchoalveolar lavage (BAL) 
fluids from c-di-GMP-(solid bars) and phosphate buffer saline PBS (open bars)-treated 
mice.
25
 Groups of BALB/c mice were treated with 10 µg c-di-GMP or PBS at day 0. Mice 
were sacrificed 1 and 7 days later, their lungs were lavaged and the lavage fluid was assayed 
for cytokines and chemokines.
25
 (Reprinted from the Biochemical and Biophysical Research 
Communications) 
 
To investigate whether c-di-GMP had any prophylactic effect, mouse mammary glands were 
treated 12 h and 6 h before infection with S. aureus produce significant prophylactic effect of 
9 
 
a 1.5 and 3.8 log reduction of the bacterial burden in tissues treated with 50 and 200 nmol of 
c-di-GMP, respectively in comparison with untreated control. These data strongly suggest 
that c-di-GMP stimulates the innate immune response (Figure 1-7).
27
 
 
 
Figure 1-7 Pretreatment protective effect of c-di-GMP.
27
 C-di-GMP was administered 12 and 
6 h before infection with S. aureus. Lactating mice were infected by intramammary 
inoculation and the infection was allowed for 10 h before mammary glands were harvested 
for bacterial colony-forming unit CFU determination. Each circle on the graph corresponds to 
the number of CFU per gram of gland for an individual gland. Mean values are indicated and 
show that prophylaxis with c-di-GMP significantly reduced the level of S. aureus 
colonization in a dose-dependent manner. *, p ˂ 0.05; ***, p ˂ 0.001.27 (Reprinted from the 
Immunology). 
Acinetobacter baumannii is a major cause of both community-associated and nosocomial 
infections worldwide. A. baumannii has rapidly developed resistance to multiple antibiotics; 
as a result, it has become difficult to treat infections caused by this pathogen. Treatments of 
mice with diverse doses of c-di-GMP reduced the bacterial burdens in both the lungs and 
10 
 
spleens. Treatments with all three dosages (12.5, 25, 50 µg) reduced the bacterial burdens in 
the spleen almost equally efficiently.  
It was shown in a recent study that mice treated intranasally with 50 μg of c-di-GMP 18 h 
prior to A. baumannii infection provided the best protection, leading to reduction in bacterial 
burden in both lungs and spleens as compared with mice treated with cGMP (Figure 1-8).
28
 
 
 
Figure 1-8 Treatment of different dosage of c-di-GMP reduce bacterial burden in lung and 
spleen.
28
 (Reprinted from the International Immunopharmacology).  
 
1.4 C-di-GMP as a mucosal vaccine adjuvant 
Pathogenic microorganisms are an extremely diverse group of living entities found in 
different environments, including the human mucosal surfaces. Indeed, the mucosal system is 
the frontline of defense against bacteria and virus invasion. Significant attempt has been 
11 
 
invested on the development of mucosal vaccination method to improve immune responses at 
both systemic and mucosal levels. The immune system is composed of two primary 
compartments: the mucosal and systemic immune systems. Vaccination at mucosal site is 
through needle-free administration and is more patient-compliant; however, mucosally 
administered antigens are generally tolerated as the host strikes to maintain mucosal 
homeostasis by responding to mucosal antigens with tolerance. As such it is challenging to 
induce mucosal immune response effectively. Currently, only four mucosal vaccines have 
been approved for human use, all based on killed or live attenuated pathogens (Table 1-1).
29
 
Due to the safety concerns with the use of killed or live attenuated pathogens, there is an 
urgent need for the development of effective mucosal vaccine adjuvants that allow for the use 
of antigens that are not based on killed or live attenuated pathogens.
30
 
 
Table 1-1 Known mucosal vaccines for human use. 
Disease Trademarks Type of vaccine 
Polio Orimune (Lederle Labs/Wyeth) Live attenuated 
Rotavirus RotaRix (GSK) Live attenuated 
Influenza FluMist (MedImmune) Live attenuated 
Typhoid Vivotif Berna, Swiss Serum, International Vaccine Institute Live attenuated 
 
The mucosal immune system has three main functions: (i) to protect the mucous membranes 
against colonization and invasion by potentially dangerous microbes, (ii) to evade recognition 
of undegraded antigens such as foreign proteins derived from absorbed food and commensal 
microorganisms, and (iii) to prevent the development of potentially harmful immune 
responses to these antigens if they do reach inside the body.
31
 
The systemic immune system functions in a normally sterile milieu and often actively 
responds to invading foreign materials. The most routine vaccines are designed for delivery 
12 
 
via the systemic system, which leads to systemic immunity, but induce a lesser degree of 
immune response at the mucosal system. Increasing numbers of studies have shown that the 
respiratory mucosa provides a valuable target site for immunization against respiratory 
pathogens.
31 
           Mucosal vaccination via the respiratory tract such as intranasal delivery shows 
advantages over other routes including the subcutaneous immunization. The intranasal 
delivery approach is easier, flexible, and more importantly, mucosal delivery demonstrate an 
ability to activate both mucosal and systemic immune responses.
32
 
         C-di-GMP has recently been recognized as a very useful immunomodulating agent in 
several in vitro and in vivo animal model studies. These studies showed the potent 
immunomodulatory (immunostimulatory and adjuvant) effect of c-di-GMP on cellular 
components of both the innate and adaptive or necessary arms of host immunity.
33-37 
         Further, Ebensen and co-workers showed that c-di-GMP has a potential application as a 
mucosal vaccine adjuvant.
38 
It was also shown by Yan and co-workers that vaccination of 
mice with pneumococcal surface adhesion A (PsaA) antigen adjuvated by c-di-GMP led to 
reduction of bacterial burdens in the lung when mice were subsequently challenged with 
Streptococcal pneumonia. More importantly, the level of reduction of bacterial burden in the 
vaccinated mice was comparable to those vaccined with PsaA + cholera toxin (CT) (Figure 1-
9).
39  
Note that CT has been regarded as the “golden standard” mucosal research vaccine 
adjuvant, however, its clinical use is restricted due to its toxicity.
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Figure 1-9 Reduction of bacterial colonization in mice immunized with PsaA-c-di-GMP.
39 
(Reprinted from the Biochemical and Biophysical Research Communications)  
 
1.5 C-di-GMP and STING protein  
 
In successful immune responses, detection of foreign materials is the first step. STING 
(stimulator of interferon genes) is an important signaling molecule for DNA and c-di-GMP-
mediated type I interferon (IFN) production via TANK-binding kinase 1 (TBK1) and 
interferon regulatory factor 3 (IRF3) pathways.
40-43 
The activation of innate immunity with 
second messengers suggests that sensing cyclic dinucleotides (CDNs)  may be essential to 
host defense against bacterial infection.
44, 45
 STING is the principle mediator for the second 
cytosolic pathway that triggers type 1 interferon, in response to sensing cytosolic dsDNA 
from infectious.
40
 STING was discovered by Glen Barber and colleagues using cDNA 
expression cloning methods as a MyD88-independent host cell defense factor expressed in 
macrophages, dendritic cells (DCs) was found to induce expression of IFN-β and NF-κB 
dependent pro-inflammatory cytokines in response to sensing cytoplasmic DNA (Figure 1-
10).
40
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Figure 1-10 Activation of interferon genes by the STING in response to the cytosolic nucleic 
acids. 
40
 (Reprinted from the Therapeutic Advances in Vaccine). 
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STING is a central sensor of cytosolic nucleic acids. STING is a MyD88-independent host 
cell defense factor that senses cytosolic nucleic acids, and in response activates TBK-1/IRF-3 
signaling cascades, inducing the expression of pro-inflammatory cytokines and IFN-β.46 The 
activating ligands for STING are CDNs, second messengers that are produced by bacteria or 
by cellular cGAS in response to binding cytosolic dsDNA. CDNs produced by bacteria and 
cGAS are structurally distinct. Less well studied, activation of STING by CDNs has also 
been shown to induce the expression of STAT6 dependent Th2 cytokines.  
It was recently shown that c-di-GMP can bind to STING.
47 
STING contains of a cytosolic C-
terminal domain (CTD) and an N-terminal region. STING CTD has been shown to 
specifically recognize c-di-GMP using the dimerization interface and imposes a symmetrical 
conformation to the bound c-di-GMP (Figure 1-11). Thus, binding of c-di-GMP does not 
cause significant conformational changes in STING CTD. Detailed analysis of the c-di-GMP-
bound STING structure revealed some asymmetrical interactions of STING with the purine 
of c-di-GMP. However, the mechanism for the elicitation of IFN production through binding 
of c-di-GMP remains unknown.  
 
Figure 1-11 C-di-GMP binds to STING dimer at the interface.
48 
(Reproduced with permission from the Immunity) 
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To evaluate the importance of STING in host defense against select virus infection in vivo, 
Sting
-/-
 (STING deficient) or control mice were infected intravenously with type 1 Herpes 
simplex virus (HSV-1) and then survival in both groups was monitored. All the Sting-
knockout mice died in 7 days of HSV-1 infection (Figure 1-12a), however, 80% of similarly 
infected wild-type control mice survived. It was determined that HSV-1 was detected in the 
brain of majority of the infected Sting
-/-
 mice, but not in the control groups at 5 days after 
infection (Figure 1-12b). Analysis of serum from the infected Sting
-/-  
mice showed a defect in 
the production of type I IFN 6 h after infection (Figure 1-12c, d ).
48
 Furthermore, Sting
-/-
 mice 
were found to be more sensitive to HSV-1 after intravaginal infection of HSV-1. This data 
indicates that STING is necessary in vivo for the effective production of type I IFN and is 
crucial for efficient protection against HSV-1 infection.
48 
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Figure 1-12 STING is required for effective in vivo host defense.
48
 a) Sting deficient animals 
(Sting
-/-
) or littermate controls (Sting
+/+
) (n = 7; approximately 8 weeks-of-age) were infected 
with HSV-1 (1x107 i.v.( intravenous)) and survival was monitored. b) Sting-/- or control mice 
were infected with HSV-1 as in panel a and brains were retrieved after 5 days for HSV-1 
plaque assays. (p.f.u., plaque-forming units). c, d) Serum from animals (n=3) infected with 
HSV-1 (1x107 i.v.) was analysed for IFNβ (c) or IFNα (d) production after 6 h. (Reprinted 
from the Immunity). 
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1.6 Preparation of c-di-GMP 
C-di-GMP has been synthesized by both enzymatic and chemical approaches. Each method 
has its advantages and disadvantages. 
1.6.1 Enzymatic synthesis of c-di-GMP 
As a natural product, c-di-GMP could be simply extracted from a natural source.
49
 It is 
possible to extract c-di-GMP from bacterial culture; however, low concentration of cellular c-
di-GMP makes this method impractical. Enzymatic synthesis of c-di-GMP suffers from low 
yield due to protein instability and strong product inhibition; however, it is possible to 
minimize these issues through the use of thermophilic diguanylate cyclase domain (tDGC) 
protein.
50
 
With the enzymatic approach c-di-GMP can be synthesized from GTP on multiple 
milligram scale. The product is typically purified by reversed phase HPLC.
51-54
 One major 
limitation with the enzymatic approach is that it is not easily amenable for the preparation of 
modified c-di-GMP. 
 
1.6.2 Chemical synthesis of c-di-GMP and analogues 
Compared with enzymatic synthesis, chemical synthesis allows for the preparation of not 
only c-di-GMP, but also analogues, potentially on much larger scales. In this approach, 
protection of 2
'
-OH of ribonucleoside and choice of phosphorylation method are two 
important considerations. So far, c-di-GMP syntheses have been carried out mostly in 
solution using the phosphotriester, phosphoramidite, H-phosphonate, and the modified H-
phosphonate approaches. 
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1.6.2.1 Phosphotriester approach 
At the beginning of the 1980s, the most general approach to oligonucleotide synthesis both in 
solution and on solid supports was the phosphotriester chemistry. The first chemical synthesis 
of c-di-GMP via the phosphotriester approach was reported by van Boom et al.
55
 where 2’-
hydroxyls of guanosine in c-di-GMP 1 were protected with tetrahydropyran-2-yl (Thp as in 
2). The coupling and cyclization reactions were effected by 2,4,6-
triisopropylbenzenesulfonyl-3-nitro-1,2,4-triazole (TPSNT) 3 to give the cyclized compound 
4 (Scheme 1-1). 
         In this chemistry, once chain assembly was completed, the internucleotide linkages 
were deprotected in a two-step fashion by treatment first with oximate and then aqueous 
ammonium hydroxide (Scheme 1-1).  
 
 
Scheme 1-1 Cyclization using the phosphotriester chemistry.
55 
Reagents and conditions: i) pyridine, TPSNT                    
20 
 
The phosphotriester chemistry worked well for the phosphorylation, however, coupling 
reactions are not as fast as some other chemistry such as phosphoramidite and H-
phosphonate. Further, removal of 2’-O-Thp protecting groups requires prolonged treatment 
with acid, which is detrimental to RNA. 
1.6.2.2 Modified phosphotriester approach 
A modified phosphotriester approach was later used by Hayakawa et al. towards the chemical 
synthesis of c-di-GMP.
56 
In this synthesis building block 6 was prepared through the 
imidazolium perchlorate (IMP)-promoted reaction of the nucleoside phosphoramidite 5 with 
2-cyanoethanol in acetonitrile, followed by oxidation with 2-butanone peroxide (BPO) and 
detritylation with dichloroacetic acid in dichloromethane. Equal molar equivalents of the 
building blocks 5 and 6 were subsequently condensed in the presence of imidazolium 
perchlorate. The resulting product was oxidized with 2-butanone peroxide followed by 
detritylation to give linear dimer 7. 
Compound 7 was treated with aqueous ammonium hydroxide to remove the 
cyanoethyl group, and the resulting product was subjected to cyclization effected by a 
mixture of triisopropylbenzenesulfonyl chloride (TPSCl) and N-methylimidazole. The fully 
protected compound 8 was deprotected first by treatment with a catalytic amount of 
Pd2[(C6H5CH=CH)2CO]3·CHCl3 in the presence of triphenylphosphine and butylammonium 
formate followed by exposure to (C2H5)3N·3HF to give the diammonium salt of 9 (Scheme 1-
2). 
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Scheme 1-2 Modified phosphotriester approach. 
Reagents and conditions: i) HOCH2CH2CN, IMP (imidazolium perchlorate), CH3CN, 30 
min; (ii) 6.7%  2-butanone peroxide (BPO)/toluene solution, 5 min; (iii) Cl2CHCOOH, 
CH2Cl2, 0ºC, 5 min; (iv) phosphoramidite 5, IMP, CH3CN, 30 min; (v) conc. aq. NH3–
CH3OH (1:10 v/v), 60 min; (vi) triisopropylbenzenesulfonyl chloride (TPSCl), N-
methylimidazole, THF, 12 h; (vii) Pd2(dba)3·CHCl3, P(C6H5)3, n-C4H9NH3
+
HCOO
-
, THF, 10 
min; (viii) (C2H5)3N·3HF, 12 h. 
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The unique strategy used in this synthesis is the use of allyloxycarbonyl and allyl groups for 
the protection of guanine bases and two internucleotide phosphates, respectively. These 
allylic protecting groups can be removed all at once by the organopalladium-catalyzed 
reaction under neutral conditions. One problem with the TBDMS as a protecting group is that 
it can undergo base-catalyzed migration.
57
 
 
1.6.2.3 H-Phosphonate approach 
Using H-phosphonate approach for synthesizing c-di-GMP was proposed by Jones et al.
58
 In 
this synthesis 5ʹ, 2ʹ-protected compound 10 was transformed into two different compounds 
11a,b and 12. Standard O-cyanoethyl-protected 11b or methyl protected phosphoramidite 
monomer 11a was first coupled with 3ʹ-H-phosphonate 12 to give a dimer H-phosphonate 13. 
It is noted that the use of 5’-hydroxyl-3’-H-phosphonate 12 circumvented additional 
protection/deprotection steps. 
 Cyclization of linear dimer 13 was then effected by adamantoylcarbonyl chloride to give the 
corresponding cyclic H-phosphonate diester, which was oxidized in situ to afford the fully 
protected cyclic c-di-GMP 14 as a mixture of diastereomers (Scheme 1-3). The deprotection 
was effected by aqueous ammonia and tetraethylammonium fluoride to make fully 
deprotected c-di-GMP 15. Purification of final product 15 was carried out by reverse phase 
HPLC (79% from 14a). 
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ib: Isobutyryl  
Scheme 1-3 H-Phosphonate approach for the synthesis of c-di-GMP. 
Reagents and conditions: i) Bis(diisopropylamino)methyl or 
bis(diisopropylamino)cyanoethyl phosphoramidite and pyridinium trifluoroacetate; (ii) 2-
chloro-4H-1,3,2-benzodiox- aphosphorin-4-one; (iii) pyridinium trifluoroacetate; (iv) tert-
butylhydroperoxide; (v) sulfonic acid resin; (vi) adamantoylcarbonyl chloride; (vii) 
methanol/NBS; (viii) pyridine/aq NH3 (1:1); (ix) TEA/HF. 
 
1.6.2.4 Modified H-phosphonate approach 
The modified H-phosphonate approach was first used by Yan and co-worker towards the 
synthesis of c-di-GMP in 2007.
59 
In this approach 2ʹ-OH was protected by the 1-(4-
chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) and H-phosphonate diesters were oxidized in 
situ with a sulfur transfer reagent to give the corresponding phosphorothioate triester 
24 
 
intermediate 16 (Scheme 1-4). The cyclization was effected by diphenyl chlorophosphate at -
40ºC to give the protected cyclic compound 17. After deprotection the final compound 18 
was obtained without the need for HPLC purification. By using a different sulfur transfer 
reagent, it is also possible to synthesize phosphorothiaote analogus of c-di-GMP where the 
non-bridging oxygen is replaced by sulfur (compound 19 and 20).
60
 
Scheme 1-4 The modified H-phosphonate chemistry in c-di-GMP synthesis. 
The modified H-phosphonat approach has its own advantages and disadvantages. The 
advantage of this approach is that the protecting groups are stable and remained intact until 
the end of the pathway. The Cpep protecting group precursor can be made easily with a high 
yield from inexpensive starting material. Like most other chemistry for the synthesis of c-di-
GMP, the modified H-phosphonate approach also involves multistep synthesis, which is 
rather time consuming. 
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As this chemistry was used for synthesizing the modified c-di-GMP and its analogue c-di-
CMP in this thesis, more detail on this chemistry will be provided in later chapters. 
1.6.2.5 Large scale synthesis of c-di-GMP  
In another route to synthesis c-di-GMP and analogues, the commercially available N-
isobutyryl-2′-O-TBS-protected guanosine phosphoramidite 21 was used as starting material. 
In total, the protected cyclic derivatives 26a-c were obtained in eight steps by extraction 
without isolation of intermediates. 
As shown in scheme 1-5, the first step in this synthesis is hydrolysis of the guanosine 
phosphoramidite 21 by treatment with pyridinium trifluoroacetate in acetonitrile containing 
two equivalents of water. The hydrolysis takes less than one min to give the corresponding H-
phosphonate diester 22 which was further treated with tert-butylamine to remove the 
cyanoethyl group followed by detrityaltion with DCA, the detritylated compound was treated 
with the other portion of compound 21 to give a dimer 23. Oxidation step was followed by 
using tert-butylhydroperoxide, or sulfurization using 3-((dimethylaminomethylidene)-
amino)-3H-1,2,4-dithiazole-5-thione (DDTT). The solution is concentrated to convert the 
solvent to methylene chloride for the second detritylation, using DCA/water, to give the 
linear dimer 24a or 24b. The  
Cyclization is effected by 3-3.5 equivalents of 5,5-dimethyl-2-oxo-2-chloro-1,3,2-
dioxaphosphinane (DMOCP) to the pyridine solution of 24a or 24b for 5-10 min. Pivaloyl 
chloride or adamantoyl chloride is used for cyclization and works well, but it was found that 
DMOCP gives slightly cleaner results compared with pivaloyl chloride. 
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Scheme 1-5 Reagents and conditions: i) pyridinium trifluoroacetate in acetonitrile /2 equiv of 
water, 1 min; ii) tert-butylamine, 10 min; iii) 3% dichloroacetic acid (DCA) 10 equiv water in 
methylene chloride, 10 min; iv) 21, 1.3 equiv 21, pyridine, acetonitrile; v) tert-
butylhydroperoxide/3-((dimethylaminomethylidene) amino)-3H-1,2,4-dithiazole- 5-thione 
(DDTT), 30 min; vi) DCA/water; vii) 3-3.5 equiv of 5,5-dimethyl-2-oxo-2-chloro-1,3,2-
dioxaphosphinane (DMOCP), 5-10 min; viii) iodine/water or 3H-1,2-benzodithiol-3-one, 5 
min. 
Final deprotection was a two-step, one-flask process was also developed where the 
final products (27 and 28) are isolated by crystallization, without the need for ion-exchange, 
or reverse-phase HPLC. The only chromatographic purification in this approach was the 
separation of the protected phosphorothioate diastereomers 25b and 25c, on a silica gel 
column.  
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Scheme 1-6 Reagents and conditions: i) tert-butylamine/acetonitrile; ii) methylamine in 
ethanol, rt, 1-2 h; iii) TEA.HF, 50°C, 60 min. 
This route to c-di-GMP synthesis is based on the most common commercially available 
guanosine phosphoramidite. The phosphoramidites of many other nucleosides, and 
analogues, are also available, thus this route should be generally appropriate for preparation 
of a wide variety of other cyclic dinucleotides, including unsymmetrical molecules, as well as 
their phosphorothioate analogues. 
The method reported here is significantly faster and more convenient than other 
approaches reported to date, allowing facile preparation of gram scale amounts of c-di-
GMP.
61 
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1.7 Choices of protecting group for 2ʹ-OH and 5ʹ-OH in RNA synthesis 
A key consideration in RNA synthesis is that 2ʹ- and 5ʹ-hydroxyls must be suitably masked 
by protecting groups that are removable under orthogonal conditions.   
1.7.1 Choices of protecting group for 2ʹ-OH 
RNAs are sensitive to both acidic and basic conditions due to the presence of 2ʹ-OH (Scheme 
1-7). In both acidic and basic conditions RNA 29 cleavage occurs through an intermediate 30 
to give the 2ʹ,3ʹ-cyclic phosphate 32 and fragment 33. Under acidic conditions, in addition to 
the cleavage, migration of internucleotide phosphate linkages between 2ʹ- and 3ʹ-postions 31 
also occurs.
62 
Under basic conditions the newly formed cyclic phosphate 32 further undergoes 
hydrolysis to generate both 2ʹ- and 3ʹ-phosphates 34 and 35, respectively. 
Thus a suitable protecting group for the 2ʹ-OH in oligoribonucleotide synthesis must 
meet the following criteria: 1) it must be stable under the acidic conditions used for repeated 
removal of dimethoxytrityl (DMTr) groups, which is the most common protecting group for 
5ʹ-OH used in both DNA and RNA synthesis. 2) It must be stable to the alkaline conditions 
that are used to cleave the assembled chain from the solid support and to remove the base and 
phosphate protecting groups. 3) It should be easily removable at the end of the synthesis 
under mild conditions that do not lead to modification of the nucleoside bases and cleavages 
or migration of the internucleotide linkages. 4) The 2ʹ-OH protecting group should not be too 
bulky to affect coupling reactions. 5) The reagents employed for the removal of the 2ʹ-OH 
protecting group should not make the purification of fully deprotected RNA too tedious or 
time-consuming.
63 
In this arena, a number of protecting groups for the 2ʹ-OH in RNA synthesis have 
been reported. Depending on their deprotection conditions, these protecting groups can be 
classified into three broad categories: acid labile, base labile, and those that are removable 
under neutral conditions.
 
29 
 
 
Scheme 1-7 Degradation of RNA in a) acidic and b) basic conditions. 
 
1.7.1.1 Acid labile 2ʹ-O-protecting groups 
About twenty-five years ago, Reese and co-workers developed the tetrahydropyranyl (Thp)
64 
and 4-methoxytetrahydropyran-4-yl (Mthp)
65
 protecting groups for the 2ʹ-hydroxyl of 
30 
 
ribonucleosides. However, it was later found that neither Thp nor Mthp groups are 
compatible with 5ʹ-O-DMTr in oligoribonucleotide synthesis, as they are not stable under the 
acidic conditions used for detritylation.
66
 Attempts to address this issue led to the 
development of 1-aryl-4-alkoxypiperidin-4-yl protecting groups that are more suitable in 
RNA synthesis, such as
 
1-(2-chloro-4-methylphenyl)-4-methoxypiperidin-4-yl (Ctmp)
67
 and 
1-(2-fluorophenyl)-4-methoxy piperidin-4-yl (Fpmp).
68 
More recently, protected acetals, such 
as  (2-nitrobenzyloxy)methyl (2-NBOM), (4-nitrobenzyloxy)methyl (4-NBOM), bis-(2-
acetoxyethoxy)methyl (ACE) and acetal levulinyl ester (ALE), have been shown to be very 
useful protecting groups for 2ʹ-OH in RNA synthesis. 
 
1.7.1.2 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp)  
Studies on the Ctmp protecting group led to the development of 1-(2-fluorophenyl)-4-
methoxypiperidin-4-yl (Fpmp) 36. Fpmp has been used successfully in the preparation of the 
ribonucleoside building blocks for the solid phase synthesis of RNA sequences.
69
  
Studies suggest that Fpmp is compatible with the acidic conditions required for detritylation 
and is readily removable at pH 3.0. Only 1.1% of migration was observed during Fpmp 
deprotection under these conditions. 
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1.7.1.3 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) 
Compared with Ctmp and Fpmp, the rate of hydrolysis of the Cpep group 37 is virtually 
independent of pH between 0.5-2.5 (figure 1-13).
70
 Further the Cpep protecting group can be 
more readily removed under acidic conditions without leading to cleavages or migration.  
In this respect Cpep is 1.3 times more stable at pH 0.5 and 2.2 in comparison with 
Fpmp and Ctmp, while it is more acid-labile at pH 3.75, making it more suitable for the 
protection of 2ʹ-OH in oligoribonucleotide synthesis. In addition, the synthesis of Cpep 
protecting group precursor involves an inexpensive material, i.e. p-chloroaniline, therefore, 
this group has the potential to be used in large scale synthesis of oligoribonucleotides. 
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Figure 1-13 Dependence of the half-lives of hydrolysis at 30°C of the 2ʹ-O-Fpmp and   2ʹ-O-
Cpep-uridines.
70 
 
1.7.1.4 2-Nitrobenzyloxymethyl (2-NBOM) and 4-nitrobenzyloxymethyl (4-NBOM) 
These nitrobenzyl derivatives are unique 2ʹ-protecting groups as their removal is achieved by 
photolysis. Unlike Ctmp, Fpmp and Cpep, the introduction of 2-NBOM and 4-NBOM 
(Figure 1-14) into ribonucleosides is not regioselective, leading to low yields in these 
reactions (20 to 40%).
71-74
 Nevertheless coupling reactions of 2-NBOM and 4-NBOM 
protected ribonucleoside phosphoramidites typically give greater than 98% yields in two to 
three minutes. This coupling efficiency is attributed to the reduced steric bulk of these 
protecting groups. Complete removal of the 2-NBOM group may be achieved under 
photolytic conditions at pH 4.  
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Figure 1-14 2ʹ-(2-nitrobenzyloxy)methyl (A) and  (4-nitrobenzyloxy)methyl (B) protected 
ribonucleoside.
 
1.7.2 Base labile 2ʹ-O-protecting groups 
1.7.2.1 Bis-(2-acetoxyethoxy)methyl (ACE) 
The 2ʹ-ACE protecting group was developed by Scaringe and co-workers.75, 76 To introduce 
ACE at 2ʹ-position, TIPDS protect 3ʹ and 5ʹ hydroxyl of compound 38. It was followed by 
addition of ACE to protect 2ʹ-hydroxyl (compound 39). TIPDS easily would be deprotected . 
It was continued with protecting specifically 5ʹ-hydroxyl with benzyhydroxy-
bis(trimethylsilyloxy) silyl chloride (SIL) protecting group to reach compound 40. (Scheme 
1-8).  
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Scheme 1-8 5ʹ-O-SIL-2ʹ -O-ACE Protected building block. Reagents and conditions: i) 
TIPDS chloride; ii) Bis-(2-acetoxyethoxy)methyl (ACE); iii) tetraethylammonium fluoride in 
acetonitrile (1.0 M, pH 8.0); iv) benzylhydroxy-bis(trimethylsilyloxy)silyl chloride, pyridine. 
 
The advantage of the ACE protecting group is that it does not migrate between 2ʹ- and 3ʹ-
positions. The coupling yield of ACE protected nucleoside phosphoramidites is as high as 
99% with the coupling time of around 90 sec. Deprotection of ACE protected 
oligoribonucleotides is a two-step process. First, the deacetylation under basic conditions, 
using 40% aqueous MeNH2, gives the 2ʹ-O-bis(2-hydroxyethoxy)methylorthoester, which is 
more labile under acidic condition compared with ACE. This is followed by the treatment 
with tetramethylethylethylenediamine (TEMED)-acetate buffer (0.1 M, pH 3.8) at 60°C for 
30 min to give the fully deprotected oligoribonucleotides. One disadvantage with the use of 
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the 2ʹ-ACE protected building blocks is their incompatibility with conventional solid phase 
synthesizers due to the use of a silyl protecting group for the 5ʹ-hydroxyls.77 
 
1.7.2.2 Acetal levulinyl ester (ALE) 
Levulinyl (Lev) was original proposed by Damha et al. as a protecting group for 2ʹ-OH in 
RNA synthesis. It was not surprising; however, that migration of the Lev group between 2ʹ- 
and 3ʹ-OH became a serious concern. Damha and co-workers later reported the acetal 
levulinyl ester (ALE) for the protection of 2ʹ-OH in RNA synthesis. Unlike Lev, the 
introduction of ALE is regiospecific with good yields. The ALE group, once installed, does 
not migrate either. 
This protecting group was shown to give 98% stepwise coupling yield in RNA synthesis.
78 
An additional utility of this group is that it allows for the preparation of siRNA pro-drugs
 
through conjugation of amino acids with the carbonyl on the ALE group.
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1.7.4 2ʹ-O-protecting groups removable under neutral conditions 
1.7.4.1 tert-Butyldimethylsilyl (TBDMS) 
The tert-butyldimethylsilyl (TBDMS) protecting group is the most widely used for protecting 
2ʹ-OH of ribonucleoside and 2ʹ-O-TBDMS protected ribonucleoside phosphoramidites 44 are 
commercially available. The TBDMS protecting group can easily be removed by the 
treatment with tetra-n-butylammonium fluoride (TBAF).
80
 However, TBDMS-based 
ribonucleoside building blocks suffer from several disadvantages: 1) incorporation of the 
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TBDMS into ribonucleosides lacks regioselectivity between 2ʹ- and 3ʹ-hydroxyl functions. 
Thus, a mixture of regioisomers is obtained (Scheme 1-9). After the desired 2ʹ-TBDMS 
ribonucleosides are obtained, there is a tendency for the TBDMS group to migrate between 
2ʹ- and 3ʹ-positions. 3) The coupling time associated with 2ʹ-TBDMS protected 
phosphoramidites in solid phase synthesis is relatively long, typically around 10 min, which 
could lead to a partial loss of the 5ʹ-O-DMTr protecting group. This relatively low reactivity 
can be attributed to the relatively large steric hindrance of the TBDMS as a protecting group. 
 
 
Scheme 1-9 Lack of regioselectivity in the TBDMS protection of DMTr protected riboside.  
Reagents and conditions: i) DCM, triethylamine. 
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1.7.3.2 [(Triisopropylsilyl)oxy]methyl (TOM) 
[(Triisopropylsilyl)oxy]methyl (TOM) group (as shown in 46) is a protected protecting 
group. Deprotection of TOM is triggered by the treatment with fluoride. Unlike the TBDMS, 
the TOM group does not migrate once it is installed at the 2ʹ-O-position; however, the 
introduction of TOM into ribonucleosides is not regiospecific, as is the case for TBDMS.
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The coupling reaction of 2ʹ-O-TOM protected phosphoramidite building blocks is very 
efficient, leading to stepwise coupling yields of 99% in three minutes. As such, the TOM 
group has been widely used in solid phase synthesis of oligoribonucleotides. 
 
 
 
Some other protecting groups for the 2ʹ-OH developed for oligonucleotide synthesis 
are shown in Table 1-2. Despite the availability of these protecting groups, there still remains 
a need for the development of RNA chemistry that meets all the requirements (Refer to 1.7.1) 
and that can be readily carried out on large scales to meet the increasing needs for therapeutic 
RNAs. 
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Table 1-2 Miscellaneous 2ʹ-protecting groups for ribonucleosides. 
Name Structure Deprotection conditions 
4-(N-dichloroacetyl-N-
methylamino)benzyloxymethy 
(4-MABOM)
82, 83
 
 
 
NH4OH, TEMED-
acetate buffer (0.1 M, 
pH 3.8), 90ºC, 30 min 
(pivaloyloxy)methyl 
(PivOM)
84, 85
 
    
  
10% piperidine, 
ammonium hydroxide, 
r.t., 3 h. 
(2-cyanoethoxy)methyl 
(CEM)
86, 87
 
 
 
TBAF in DMSO (0.5 
M) with 5% 
nitromethane, r.t.,   5 h. 
[2-(toluene-4-sulfonyl) 
ethoxy]methyl (TEM)
88, 89
 
 
 
TBAF in THF (1.0 M), 
10% piperidine, r.t., 20 
h. 
 
1.7.4 Choices of protecting group for 5ʹ-OH in RNA synthesis 
Protecting groups for 5ʹ-OH must be compatible with others, particularly the 2ʹ-O-protecting 
group in RNA synthesis. With the exception of the ACE chemistry, where a silyl protecting 
group is used for 5ʹ-OH, most RNA chemistry uses an acid labile protecting group to mask 
5ʹ-OH.90 The most popular protecting groups for 5ʹ-OH are 9-(p-tolyl)xanthene (Px or pixyl) 
and dimethoxytrityl (DMTr) groups (Figure 1-16). 
There are some advantages in using the pixyl group. The pixyl group is about 3 times 
more readily removable under acidic conditions compared with the DMTr group,
90
 therefore 
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its use shortens the exposure of oligonucleotides to acids. When 2ʹ-OH is protected by an 
acetal group, such as Cpep, this feature is particularly useful as shortened acid exposure 
minimizes the potential loss of the Cpep group. In this regard, the pixyl group is completely 
deprotected with trifluoroacetic acid in the presence of pyrrole in 10 seconds. Under this 
condition, Cpep is completely intact.    
 
 
Figure 1-15 DMTr and Pixyl groups. 
1.8 Labelling c-di-GMP at 2ʹ position 
Despite the importance of c-di-GMP in regulating bacterial processes, and its potential 
applications in modulating immune systems in mammalian, there is a general lack of 
knowledge in the cellular and tissue distributions of c-di-GMP, and proteins that bind to c-di-
GMP. In this respect, it would be beneficial to introduce a functional group to c-di-GMP that 
will allow for the tracking of c-di-GMP and identification of c-di-GMP binding proteins. In 
2010 Serge L. Beaucage and co-workers demonstrated a strategy for the synthesis of the 
propargylated c-di-GMP 57. The synthesis was based on two commercially available starting 
materials 47 and 50 as building blocks. The 2ʹ-propargylated monomer 49 was readily 
accessible in two steps from 2’-O-propargyl-5’-O-DMTr-N2-isobutyrylguanosine. This 
monomer was then coupled with phosphoramidite 50 to generate the corresponding linear 
dimer 52. After removal of the DMTr group, phosphitylation led to formation of a mixture of 
two phosphoramidites 54 and 55, which afforded the fully protected cyclic dimer 56 upon 
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cyclization. Deprotection finally yielded c-di-GMP bearing a propargyl group at the 2’-
position (Scheme 1-10).  
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Gua, guanin-9 yl;  iBu, isobutyryl; DMTr, 4,4′-dimethoxytrityl; TBDMS, tert-
butyldimethylsilyl; Lev, levulinyl. 
Scheme 1-10 Reagents and conditions: i) levulinic anhydride, pyridine, 25°C, 16 h; ii) 80% 
AcOH, 3h; (iii) 1H-tetrazole, MeCN, 49, 2 h, 25°C; (iv) tert-BuOOH/decane, 30 min; (v, vi) 
hydrazine hydrate/AcOH/C5H5N, 15 min, then 2,4-pentanedione, 5 min; (vii) 80% AcOH, 3 
h, 25°C.  (viii) (i-Pr2N)2POCH2CH2CN, 1H-tetrazole (1.0 equiv at the rate of 0.25 equiv/15 
min), MeCN, 1 h; (ix) 1H-tetrazole (2 equiv), MeCN, 16 h; (x) conc. aq. NH3, 30 h, 25°C; 
(xi) Et3N•3HF, 20 h, 25°C.  
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Objective 
This thesis addressed two objectives. First, the cytidine analogue of c-di-GMP, i.e. c-di-CMP, 
was synthesized. As described previously in the introduction, the structural requirements for 
cyclic dinucleotides as immunostimulating agents and vaccine adjuvants remain unclear. 
Availability of c-di-GMP analogues, such as c-di-CMP, will allow for the exploration of 
structure-activity relationship in this vein. The cytidine analogue was chosen as the synthetic 
target because the immunostimulatory activity and adjuvanticity of c-di-CMP have never 
been evaluated. 
Second, synthesis of c-di-GMP analogues that are modified at one of the 2ʹ-OH 
functionalities of guanosine was attempted. The ultimate goal of this study relates to the 
labeling of c-di-GMP by a fluorophore or biotin (Scheme 1-11) that will allow for tracking 
cellular and tissue distribution of c-di-GMP, and elucidation of proteins that bind to c-di-
GMP. Towards this goal, synthesis of guanosine bearing a reactive group, such as azido and 
amino, at 2ʹ-OH through an alkyl linker was explored. 
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Scheme 1-11 Label c-di-GMP with a fluorophore (A) or biotin (B) through at 2ʹ-position 
through an alkyl linker. 
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Chapter 2 
Results and discussion 
2.1 Synthesis of c-di-CMP 
In the modified H-phosphonate approach, both oligonucleotide phosphates and 
phosphorothioates can be readily isolated in high yields due to their stability. Fully protected 
c-di-CMP can also be purified to very high purity. The protecting groups are chosen in a 
fashion where they can be removed without leading to cleavage of phosphodiester linkages or 
modification to the nucleobase residues. In this thesis, 1-(4-chlorophenyl)-4-ethoxypiperidin-
4-yl (Cpep) was used to mask 2ʹ-hydroxyls due to the advantages outlined previously in 
Chapter 1. 
2.1.1 Chemical synthesis of c-di-CMP  
The synthesis of c-di-CMP was initiated by the TIPDS protection of the commercially 
available N4-benzoyl-cytidine 62. This reaction was accomplished by treating N4-benzyol-
cytidine 62 with TIPDS chloride in pyridine at 0ºC to give compound 63 in 85% yield. 
Subsequently the 2ʹ-OH of 63 was protected with the 1-(4-chlorophenyl)-4-ethoxypiperidin-
4-yl (Cpep) group by the treatment with enol ether in the presence of trifluoroacetic acid in 
dry dichloromethane. Without purification the 2ʹ-O-Cpep-3ʹ,5ʹ-TIPDS protected N4-benzyol-
cytidine was subjected to TIPDS deprotection by the treatment with tetraethylammonium 
fluoride in acetonitrile (1.0 M, pH 8.0) to give compound 64  in 81% overall yield. The 5ʹ-
OH of the compound 64 was subsequently protected with pixyl by the treatment with pixyl 
chloride in pyridine to give compound 65 in 87% yield (Scheme 2-1). The monomer 65 was 
then further transformed into two building blocks. First, treatment of the monomer 65 with p-
tolyl H-phosphonate and pivaloyl chloride in pyridine gives the corresponding 3ʹ-H-
phosphonate 66 in 92% yield after column chromatography. On the other hand, the monomer 
65 was treated with levulinic anhydride in pyridine in the presence of a catalytic amount of 
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dimethylaminopyridine to give the corresponding 3ʹ-O-Lev protected monomer. Removal of 
5ʹ-pixyl with trifluoroacetic acid in the presence of pyrrole led to the building block 67 in 
82% yield.  
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Scheme 2-1 Chemical synthesis of c-di-CMP. Reagents and conditions: i) (i-Pr)2Si(Cl)OSi(i-
Pr)2(Cl), C5H5N; ii) Cpep enol ether, CH2Cl2, CF₃CO₂H, 5h; iii) tetraethylammonium 
fluoride (1.0 M, pH 8.0), iv) PxCl, C5H5N, 40 min; v) H-phosphonate, pivaloyl chloride, 
C5H5N, 0ºC, 1 h; vi) (Lev)2O, CH2Cl2, dimethylaminopyridine, Et3N, 30 min; vii) pyrrole, 
CH2Cl2, CF3CO2H, 30 sec. 
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The H-phosphonate 66 and the monomer with free 5ʹ-OH 67 were then subjected to treatment 
with pivaloyl chloride to give the corresponding H-phosphonate diester, which was 
subsequently transformed into S-(p-tolyl)phosphorothioate triester 68 by treatment in situ 
with 2-phenylsulfanyl-1H-isoindole-1,3(1H)-dione. The phosphorothioate triester 68 is stable 
and was isolated in a good yield (75%) by column chromatography.  
  
 
Scheme 2-2 Chemical synthesis of c-di-CMP. Reagents and conditions: i) (CH3)3CCOCl, 
C5H5N, sulfur transfer reagent (Scheme 2-5), 30 min. 
Removal of 3ʹ-levulinyl from the fully protected linear dimer 68 was effected by the 
treatment with hydrazine hydrate. The resulting product from levulinyl deprotection, Px-
Cp(s)C-OH* 69, was then transformed into the corresponding H-phosphonate Px-Cp(s)Cp(H) 
70 by treatment with p-tolyl H-phosphonate in the presence of pivaloyl chloride. Px-
Cp(s)Cp(H) 70 was subsequently treated with trifluoroacetic acid in the presence of pyrrole 
to remove the 5ʹ-pixyl protecting group (compound 71). Under this condition, pixyl group is 
completely removed in as short as 30 seconds.  
*Abbreviation is followed for protected oligonucleotides in which nucleoside residues and 
internucleotide linkages are italicized if they are protected in some defined way. In the 
present context, Cʹʹ represents cytidine protected on N-4 with a benzyl group; and p(s ʹ) 
represents an S-phenyl-protected phosphorothioate. 
48 
 
The purified dimer H-phosphonate HO-Cp(s)Cp(H) 71 was subjected to cyclization effected 
by diphenylchlorophosphate at -40ºC. It is noted that this reaction must be carried out under 
high dilution conditions to avoid formation of linear oligomer products. The high dilution 
was effected by the slow addition of a solution of HO-Cp(s)Cp(H) 71 in dry pyridine to a 
solution of diphenylchlorophosphate in dry dichloromethane. The purified fully protected 
cyclic dinucleotide 72 showed one signal in the 
31
P NMR spectrum (Figure 2-1). 
 
Scheme 2-3 Chemical synthesis of c-di-CMP. Reagents and conditions: i) C5H5N, 
NH2NH2•H2O, C2H4O2, H2O; ii) H-phosphonate, C5H5N, (CH3)3CCOCl , 0ºC, 1 h; iii) 
CH2Cl2, pyrrole, CF3CO2H, 30 sec; iv) (PhO)2P(O)Cl, CH2Cl2, C5H5N, sulfur transfer 
reagent, -40ºC. 
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Figure 2-1 
31
P-NMR of fully protected c-di-CMP 69. 
 
It is noted that during the removal of levulinyl group, hydrazine hydrate must be added as a 
pre-mixed solution with acetic acid-pyridine-water, as hydrazine can modify nucleobases if 
not neutralized by acetic acid. The mechanism for the deprotection of levulinyl ester is shown 
in scheme 2-2. Acid will activate the ketone of the lev group in compound 75, which leads to 
the nucleophilic addition of hydrazine (compound 76) and subsequent condensation to give 
the compound 77.  In the next step, the second nitrogen of hydrazine in compound 77 
undergoes nucleophilic attach at the carbonyl group of the ester, which leads to deprotection 
of the lev group from the 2ʹ-OH (compound 78).  This reaction leads to the formation of a 
cyclic hydrozoneamide 79 as a by-product (shown in Scheme 2-4). The excess of hydrazine 
should be treated with pentane-2,5-dione prior to aqueous workup. 
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Scheme 2-4 Deprotection mechanism of Lev protecting group. 
 
Deprotection of the fully protected cyclic dinucleotide 72 involved a three-step process. First, 
compound 72 was treated with 2-nitrobenzaldoxime in the presence of N,N,Nʹ,Nʹ-
tetramethylguanidine. This is followed by incubation in concentrated aqueous ammonium 
hydroxide at 55ºC for 12 hours. The partially protected c-di-CMP, i.e. all protecting groups 
except 2ʹ-O-Cpep 73 were removed, was then subjected to incubation in a mixture of 
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dimethylacetamide (DMA) and triethylammonium formate buffer (0.5 M, pH 2.52). Note that 
this mixture showed an apparent pH of 4.0 with a pH meter. After the reaction mixture was 
heated at 40ºC for 5 hours, the products were cooled, and the pH was adjusted to 7.0 with 
triethylamine. The products were then extracted with chloroform to remove DMA. The fully 
deprotected c-di-CMP was then precipitated by addition of n-butanol. This precipitation 
procedure also removes the organic salts that were generated in the deprotection process. The 
product was then eluted through an Amberlite (IR120, Na
+ 
form) cation-exchange column to 
give the sodium salt of c-di-CMP. The product was characterized by 
1
H and 
31
P NMR, 
reverse phase HPLC, and mass spectrometry. As shown in 
31
P NMR (figure 2-2) and HPLC 
profile (Figure 2-3), the c-di-CMP was quite pure. The above mentioned synthetic strategy 
allowed us to obtain the fully deproteced c-di-CMP 74 in pure form simply by precipitation 
after deprotection, without using HPLC purification, which makes the process efficient for a 
large scale synthesis.   
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Scheme 2-5 Chemical synthesis of c-di-CMP. Reagents and conditions: i) 2-
Nitrobenzaldoxime, N,N,N′,N′-Tetramethylguanidine, 16 h; ii) aq. NH3 55ºC, 15 h; iii) 
acetonitrile, NEt3-HCOOH buffer (0.5 M, pH 2.52), 40ºC, 5 h. 
 
 
 
 
 
 
Figure 2-2 
31
P-NMR of fully deproteted c-di-CMP 74 (
1
H decoupling). 
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Figure 2-3 HPLC profile for c-di-CMP 74. 
The HPLC analysis was carried out on a C18 reverse phase Clarity 3u Oligo rp 3 micron 
column (50 x 4.60mm). The column was eluted at 0.80 mL/min with the following program: 
linear gradient of triethylammonium acetate buffer (10 mM pH 7.0) – acetonitrile (100:00 v/v 
to 85:15 v/v) over 10 minutes and then isocratic elution. 
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Scheme 2-6 Mechanism of action of 2-NBO. 
The role of 2-NBO in this deprotection sequence is shown in Scheme 2-6. The oximate first 
displaces the S-(p-tolyl) group on the phosphorothioate to give the corresponding oximate 
ester 80 (Scheme 2-6). The latter subsequently undergoes β-elimination upon incubation in 
aqueous ammonium hydroxide to give corresponding phosphate diester, releasing 2-
nitrobenzonitrile as by-product (compound 83). The use of 2-NBO to deprotect 
phosphorothioate triester is essential as direct treatment of phosphorothioate triesters with 
ammonium hydroxide leads to undesired chain cleavages on the phosphate backbone.
92 
2.2 Synthesis of c-di-GMP modified at 2ʹ-O-position with a C6 linker 
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As we discussed in objective Scheme 1-11 the purpose of synthesizing c-di-GMP modified at 
2ʹ-O-position is to label it with fluorophore or biotin. The biotinated c-di-GMP entails a 
triazole that is very close to c-di-GMP, which could interfere with the binding of c-di-GMP 
with its receptor. As such, it would be advantageous to use a longer linker that is less likely to 
affect the binding. In this thesis, a C6-alkyl chain with terminal alkyne is used for the 
conjugation purpose.  
 
2.2.1 The chemical synthesis of guanosine modified at 2’-O-position with a 
C6 linker. 
 
In this thesis, a C6 alkyl linker was used to attach either biotin or fluorophores to 2ʹ-OH. The 
synthesis started with the preparation of 6-bromohexanol 85 by treating 1,6-hexandiol 84 
with hydrobromic acid (48%) in toluene as the commercially available 6-bromohexanol is 
rather expensive. The hydroxyl in 6-bromohexanol was subsequently protected with a benzyl 
group by treatment with benzyl bromide in the presence of sodium hydride (Scheme 2-7). It 
is noted that the compound 86 must be distilled under reduced pressure to remove all residual 
moisture; or the subsequent alkylation reaction will not proceed. 
 
Scheme 2-7 the synthesis of 6-bromohexyl benzyl ether 86. Reagents and conditions: i) HBr, 
toluene, reflux 2 h; ii) NaH, THF, 6-bromo-hexanol, benzyl bromide, 24 h. 
In the next step, diaminopurine riboside 87 was alkylated with 6-bromohexyl benzyl ether 86 
Scheme 2-8. It is worth noting that all of the 2ʹ-, 3ʹ-, and 5ʹ-hydroxyls was protected in the 
alkylation. As a consequence, the alkylation led to the formation of a mixture of products. 
Considering the fact that the 2ʹ-OH is slightly more acidic than 3ʹ- and 5ʹ-hydroxyls in 
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ribonucleosides, it is perhaps not surprising that the 2ʹ-O-alkylated product 88 was isolated in 
ca. 35% yield.
80 
In earlier attempts, guanosine, instead of diaminopurine riboside was used as 
the starting material for this alkylation reaction, which inevitably led to alkylation at the 
guanine residue. Attempts were also made to protect 3ʹ- and 5ʹ-hydroxyls with protecting 
groups such as TIPDS. However, TIPDS tends to be cleaved during the alkylation reaction (It 
is not shown). The 2ʹ-O-alkylated diaminopurine riboside 88 was subsequently protected with 
TIPDS at the 3ʹ- and 5ʹ-positions 89 in good yield (Scheme 2-8).  
 
Scheme 2-8 Chemical synthesis of guanosine modified at 2’-O-position with a C6 linker. 
Reagents and conditions: i) NaH, (CH₃)₂NCH, 48 h; ii) (i-Pr)2Si(Cl)OSi(i-Pr)2(Cl), C5H5N. 
Then it was followed by acetylation of 2ʹ-O-alkyl-3ʹ,5ʹ-O-TIPDS diaminopurine riboside 89 
to get the desired N2-isobutyryl diaminopurine riboside 90, which was obtained in 65% yield. 
It was continued by converting 90 to guanosine (Scheme 2-9). 
57 
 
 
Scheme 2-9 Chemical synthesis of guanosine modified at 2’-O-position with a C6 linker. 
Reagents and conditions: i) tetraethylammonium fluoride (1.0 M, pH=8.0), CH3CN; ii) 
(CH3)2CHCOCl, C5H5N; iii) aq. NH3 55ºC, 20 h; iv) CH₃CN(CH₃)₂, CH₃COOH, H2O, 
NaNO2, 7 days. 
 
To get the desired acetylated compound 90 three steps combined to getter, as can be seen in 
Scheme 2-9. A literature procedure to first bisacylate 2,6-diamine followed by selective 
deacylation of the N6-acyl group was used. This was accomplished by first treating with 
isobutyryl chloride to acylate both 2- and 6-amine (intermediate 89i), and then using aqueous 
ammonia (Scheme 2-9). 
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Scheme 2-10 Chemical synthesis of guanosine modified at 2’-O-position with a C6 
linker. Reagents and conditions: i) C5H5N, (CH3)2CHCOCl; ii) aq. NH3 55ºC, 20 h. 
In purpose of converting 90 to guanosine, in earlier attempts to accomplish this goal, an 
enzymatic approach was used. Thus, either 2ʹ-O-alkylated-3ʹ,5ʹ-O-TIPDS protected 
diaminopurine riboside 90 or 2ʹ-O-alkylated diaminopurine riboside 89 was treated with 
adenosine deaminase in aqueous DMSO in the presence of 
tris(hydroxymethyl)aminomethane hydrochloride. The reactions were extremely slow (>7 
days) and the conversion was very low, most probably due to the poor solubility of the 
substrate. An alternative deamination approach was found to be more effective. Thus 2ʹ-O-
alkylated-3ʹ,5ʹ-O-TIPDS protected diaminopurine riboside 90 was first treated with sodium 
nitrite in dimethylacetamide to generate a diazonium species, followed by treatment with 
aqueous acetic acid at 4°C. The reaction was also rather slow (7 days) and addition of 
59 
 
multiple portions of sodium nitrite was required to make compound 92, however, 
deamination was complete and the procedure was found to be reproducible (Scheme 2-11). 
During this reaction, TIPDS protecting group was found to be partially hydrolyzed. In order 
to simplify purification, a treatment with TEAF was used to remove TIPDS group completely 
before the deamination reaction (Scheme 2-9). The purified product was then treated with 
TIPDS chloride to mask 3ʹ- and 5ʹ-OH 92. 
 
Scheme 2-11 Chemical synthesis of guanosine modified at 2’-O-position with a C6 linker. 
Reagents and conditions: i) (i-Pr)2Si(Cl)OSi(i-Pr)2(Cl), C5H5N; ii) Pd/C (10% wt), H2; iii) a) 
4-Toluenesulfonyl chloride, CH2Cl2 ; b) DMF, LiCl, NaN3. 
In order to install a handle for conjugation at the 2ʹ-O-position, the benzyl group needs to be 
removed (Scheme 2-11). To our surprise, catalytic hydrogenation reaction failed under many 
different conditions (Table 2-1).      
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Scheme 2-12 Hydrogenation reaction condition. 
Table 2-1 Different conditions attempted for the debenzylation of alkyl side chain. 
Solvent Catalyst Hydrogen 
source 
Other reagents Results 
Ethanol Pd/C 10% (1.1 mol%) H2 (g)  50 psi No Reaction 
Methanol Pd/C 10% (1.1 mol%) H2 (g) 50 psi No Reaction 
Ethyl 
acetate  
Pd/C 10% (1.1 mol%) H2 (g) 50 psi No Reaction 
Methanol Pd/C 10%, Pd(OH)2 
(1.1 mol%)  
H2 (g) 50 psi No Reaction 
Methanol Pd/C 10% (1.1 mol%) H2 (g) 50 psi, 2,6-lutidine 
(0.1 eq),  45°C 
No Reaction 
Methanol Pd/C 10% (1.1 mol%) H2 (g)  100 psi  No Reaction 
Methanol Pd/C 10% (1.1 mol%) Triethylsilane 
(10.0 eq) 
 No Reaction 
Methanol  Pd/C 10% (1.1 mol%) H2 (g)  50psi, 
Trichloroacetic acid 
No Reaction 
Dichlorome
thane 
  borontribromide  
(0.1 M ), -78°C, 2h 
No Reaction 
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As can be seen in table 2-1, hydrogenation reaction in different solvents such as methanol, 
ethanol and ethyl acetate, at 50 psi in the presence of catalytic amount of Pd/C did not lead to 
the removal of the O-benzyl group after 4 days. Other conditions, such as hydrogenation in 
the presence of triethylsilane or lutidine, also failed to give the desired product.  
             Lewis acid promoted debenzylation, on the other hand, led to the formation of a 
complex mixture. It was found that a excess amount of palladium catalyst was required for 
successful debenzylation 91, however, only after a lengthy reaction time (7 days) (Scheme 2-
12). The reason for the requirement of stoichiometric amount palladium in this reaction is 
unclear at this time. Attempts were made to determine if the difficulty in debenzylation is due 
to the presence of the alkyl chain attached to 2ʹ-OH of ribose or not. Thus hydrogenation 
reactions of 6-bromohexylbenzyl ether 86 in THF were carried out under hydrogen 
atmosphere (50 psi) and the presence of catalytic amount of Pd/C (Scheme 2-13). 
 
 
Scheme 2-13 Hydrogenation reaction condition for bromohexyl-6-benzyl ether. 
Interestingly, under these conditions, the starting material was completely consumed in 24 h 
to give the debenzylated product 85.  
 In the subsequent steps, the hydroxyl group on the 2ʹ-linker of compound 92 
was transformed into mesylate or tosylate to facilitate the nucleophilic substitution with 
azide. The reaction between 92 and mesyl chloride in dichloromethane in the presence of 
triethylamine was completed in 10 min. Upon evaporation, the products were subsequently 
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treated with sodium azide in dry DMF. Surprisingly, this reaction failed to give the 
corresponding azido product. Addition of molar equivalence of lithium chloride or catalytic 
amount of 18-crown-6 to the reaction mixture led to the formation of a new product, in 
addition to what appear to be the hydrolyzed product (i.e. displacement of mesylate by OH); 
however, the identity of the new product could not be confirmed by mass spectrometry and 
NMR. Further, treatment of this product under catalytic hydrogenation conditions failed to 
give an amine. Note that if the desired azido product were successfully produced, then 
catalytic hydrogenation would have given the corresponding amine. At the time of this 
writing, it remains uncertain what are the causes of the failed mesylate-azido displacement 
reaction. 
An attempt to transform 92 into the corresponding azido compound using a 
Mitsunobu reaction also failed. In this respect, 92 was treated with diethyl azodicarboxylate, 
triphenylphosphine, and diphenyl phosphoryl azide, but no reaction was observed after a day. 
Similarly, a literature procedure to transform alcohol into azide by treatment with N-(p-
toluenesulfonyl) imidazole, tetra-n-butylammonium iodide, triethylamine, and sodium azide 
was also unsuccessful. 
 Due to the difficulty encountered in the above transformation, attempts were also 
made to convert compound 92 to the corresponding terminal alkyne 96 through a Swern 
oxidation – Corey Fuch sequence (Scheme 2-14). 
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Scheme 2-14 Conversion of hydroxyl group on the 2ʹ-linker to alkyne through a Swern 
oxidation – Corey Fuch sequence. 
               Due to reasons unknown at the time, Swern oxidation did not give the 
corresponding aldehyde 95, as the 
1
H NMR spectrum of the oxidation product did not reveal 
a characteristic aldehyde proton. 
 
2.3 Conclusion and future work on labeling of c-di-GMP at 2ʹ-position  
Due to the challenges that were encountered in accessing the building block with azido 
substitution (compound 94), future work will consider alkylation of diaminopurine riboside 
with a reagent that bears a terminal alkyne. This modification will allow for conjugation of c-
di-GMP bearing the alkynyl functionality with azido biotin (B) or azido fluorophore (A) 
(Scheme 2-15). 
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Scheme 2-15 Conjugation of c-di-GMP bearing the alkynyl functionality with azido biotin 
(B) or azido fluorophore (A).
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Chapter 3 
Experimental 
1
H NMR spectra were measured at 600 MHz with a Bruker AV600 spectrometer, AV400 and 
AV300.  
13
C at 75 MHz or 151 MHz, 
31
P at 121 MHz. J values are given in Hz. Chemical 
shifts are given in ppm.  
3.1 EI, FAB mass spectrometric measurements 
Prior to December/2013 all samples were run on a Kratos/MSI Concept 1S instrument at 6kV 
accelerating potential. Resolution was 1000 for nominal mass spectra and 10,000-15,000 for 
high resolution runs. FAB bombardment used an Ion Tech atom gun employing Xe gas. Data 
were processed using Mach3 software. After May 1, 2014 all spectra were run on a Thermo 
DFS high resolution spectrometer at 5 kV accelerating potential. Resolution was 1000 for 
nominal mass spectra and 10,000-15,000 for high resolution runs. FAB bombardment used a 
Cs ion gun. Data were processed using Xcalibur software. 
3.1.1 Electrospray mass spectrometric measurements  
Samples in solution were run by infusion (syringe pump) or liquid chromatography using an 
Agilent 1100 LC system. All detection (ESI) was carried out on a Bruker HCT Ultra ion trap 
system. All qualitative and quantitative data were processed using Bruker Data Analysis 
software. All ESI data were low resolution due to the poor ionization of the nucleosides. 
3.1.2 MALDI mass spectrometric measurements 
MALDI mass spectra were generated on a Bruker Autoflex II/TOF/TOF instrument using 
stainless steel sample plates. Samples were run neat or in a suitable matrix determined by 
sample requirements. Data were processed using Bruker FLEX Analysis software. 
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3.2 Chromatography 
 Dessican 230–400 mesh silica gel 60 was used for flash column chromatography. Thin layer 
chromatography was performed on Silicycle Silica Plate F-254 TLC plates using the 
following system: 
System A: methanol- dichloromethane (15:85 v/v) 
System B: methanol- dichloromethane (10:90 v/v) 
System C: methanol- dichloromethane (5:95 v/v) 
3.2.1 Solvents and Chemicals 
Toluene was dried by heating under reflux over sodium in the presence of benzophenone for 
4 h and then distilled. Dimethylformamide was heated at 60ºC for 2 h, pyridine, was dried by 
heating under reflux over calcium hydride for 4 h and dichloromethane was dried by P2O5 
and then distilled . All the distilled solvents were stored over activated 4 Å molecular sieves. 
All other reagents were purchased from Sigma-Aldrich or TCI America and were used 
without further purification unless stated otherwise. 
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3.3 Preparation of compounds 
4-N-Benzoyl-3ʹ,5ʹ-O-(1,1,3,3-tetraisopropyldisiloxyl) cytidine  63 
 
 
 
 
N-benzoylcytidine 62 (2.20 g, 6.33 mmol) was dried at 80°C in vacuo for 5 h and then it was 
dissolved in anhydrous pyridine (15 ml), followed by addition of 1,1-dichloro-1,1,3,3-
tetraisopropyldisiloxane 96 (2.2 ml, 6.97 mmol) while the temperature was kept at 0°C (ice-
water bath). After 5 h the products were concentrated under reduced pressure, and the residue 
was partitioned between dichloromethane (60 ml) and saturated aqueous sodium hydrogen 
carbonate (50 ml). The layers were separated and the aqueous layer was back-extracted with 
dichloromethane (3x10 ml). The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. The residue was fractionated by short column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (98:2 v/v) were combined and concentrated under reduced 
pressure to give the compound 63 as a colorless froth (3.20 g, 85.7%). 
1
H NMR data are in 
agreement with literature values.
92 
ESI-MS [M-H]
 ¯ 
found 589.4, C28H43N3O7Si2 required 589.26 
δH [(CD3)2SO]: 11.32 (1 H, s),  8.19 (1 H, d, J = 7.5 Hz), 8.02-7.99 (1 H, m), 7.65-7.60 (1 H, 
m), 7.53-7.48 (1 H, m), 7.38-7.36 (1 H, m), 5.81 (1 H, d, J = 3.9 Hz), 5.64 (1 H, s), 4.23 (1 H, 
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d, J =13.5 Hz), 4.23 (1H, d, J = 13.5 Hz), 4.13 (3 H, s), 3.94 (1 H, d, J = 13.2 Hz), 0.95-1.06 
(m, 28).  
Rf : 0.48 (system C). 
2ʹ-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-4-N-benzoylcytidine   64 
(C29H32ClN4O7, 584.203)  
 
 
 
4-N-Benzoyl-3ʹ,5ʹ-O-(1,1,3,3-tetraisopropyldisiloxyl) cytidine 63 (4.10 g, 6.95 mmol) and 1-
(4-chlorophenyl)-4-ethoxy-1,2,5,6-tetrahydropyridine 37 (4.94 g, 20.8 mmol) were 
evaporated with dry toluene (2x10.0 ml) and then dissolved in dry dichloromethane (20 ml), 
followed by addition of dry trifluoroacetic acid (1.00 ml, 13.5 mmol). After 5 h, triethylamine 
(1.64 ml, 11.8 mmol) was added. The products were partitioned between dichloromethane 
(30 ml) and saturated sodium hydrogen carbonate solution (30 ml). The organic layer was 
separated, dried with MgSO4 and concentrated under reduced pressure. The residue was 
dissolved in acetonitrile (20 ml) followed by addition of a solution of tetraethyl ammonium 
fluoride in acetonitrile (20 ml, 1.0 M, pH 8.0). The products were concentrated under reduced 
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pressure after 30 min. The residue was purified by short column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane-methanol (97:3 v/v) 
were pooled and concentrated under reduced pressure to give the compound 64 as a colorless 
froth (3.30 g, 81%). 
ESI-MS [M-H]
¯
 found 584.1, C29H32ClN4O7 required: 584.20 
δH[(CD3)2SO]:  11.31 (1 H, s), 8.48 (1 H, d, J = 7.2), 8.00-8.02 (2 H, m), 7.66-7.61 (1 H, m), 
7.54-7.49 (2 H, m), 7.39 (1 H, d, J = 9.0), 7.18 (2 H, d, J = 9.0), 6.92 (2 H, d, J = 9.0), 6.13 (1 
H, d, J = 6.0), 5.26 (1 H, t, J = 12.0), 5.15 ( 1 H, d, J = 6.1), 4.45-4.41 (1 H, dd, J = 5.1 and 
6.6), 4.02-4.06 (1 H, m), 3.97-3.96 (1 H, m),  3.65-3.61 (2 H, m), 3.43-3.46 (2 H, m), 3.19-
3.14 (1 H, m), 3.04-3.01 (1 H, m), 2.90-2.89 (1 H, m), 1.79-1.84 (4 H, m), 0.91 (3 H, t, J = 
13.8). 
δC[(CD3)2SO]: 15.5, 32.4, 33.6, 45.8, 46.1, 55.4, 61.8, 71.2, 74.1, 86.9, 99.7, 117.6, 122.3, 
128.9, 128.9, 129.0, 133.2, 149.7 
Rf : 0.62 (system C). 
 
 
 
 
 
 
 
 
 
 
 
70 
 
4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-O-[9-(p-tolyl)xanthen-9-
yl] cytidine 65 
 
 
2ʹ-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-4-N-benzoylcytidine 64 (2.50 g, 4.28 
mmol) was evaporated with dry pyridine (2x5 ml). The residue was dissolved in anhydrous 
pyridine (25 ml), followed by addition of 9-chloro-9-(p-tolyl)xanthene 98 (1.57 g, 5.12 
mmol). After 40 minutes a mixture of methanol - N-methylmorpholine (3 ml, 1:1 v/v) was 
added. The products were partitioned between dichloromethane (60 ml) and saturated sodium 
hydrogen carbonate solution (40 ml). The organic layer was separated and the aqueous layer 
was back extracted with dichloromethane (2x10 ml). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. The product was purified by short column 
chromatography on silica gel. The appropriate fractions which were eluted with 
dichloromethane-methanol (99:1 v/v) were combined and concentrated under reduced 
pressure to give the compound 65 as a yellow foam (3.20 g, 87%). 
ESI-MS [M-H]
¯
 found 855.1, C49H47ClN4O8 required 855.39 
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δH[(CD3)2SO]: 11.35 (1 H, s), 8.30-8.20 (1 H, d), 8.02-7.99 (2 H, m), 7.66-7.61 (1 H, m), 
7.54-7.15 (21 H, m), 6.94 (2 H, d, J = 9.3), 6.12 (1 H, d, J = 6.0), 5.26 (1 H, d, J = 5.4), 4.55 
(1 H, t, J = 10.5), 4.06-4.05 (1 H, m), 3.57 (1 H, t, J = 3.0), 3.40-3.42 (1 H, m), 3.25-3.22 ( 3 
H, m), 3.10-2.93 (3 H, m), 1.91-1.82 (4 H, m), 1.00 (3 H, t, J = 9.2). 
Rf : 0.58 (system C) 
 
4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-O-[9-(p-tolyl)xanthen-9-
yl] cytidine 3ʹ-H phosphonate, triethylammonium salt 66 
 
 
 
p-Tolyl H-phosphonate (1.19 g, 4.86 mmol) was co-evaporated with triethylamine (1.46 ml, 
11.4 mmol) and methanol (8 ml). 4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-
yl]-5ʹ-O-[9-(p-tolyl)xanthen-9-yl] cytidine 65 (1.60 g, 1.87 mmol) was added and the mixture 
was evaporated with dry pyridine (2x5 ml) followed by addition of dry pyridine (40 ml). 
While temperature was kept at 0°C (ice-water bath) distilled pivaloyl chloride (0.80 ml, 6.54 
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mmol) was added dropwise in 5 min. The reaction mixture was stirred for 1 hour at 0°C (ice-
water bath) then the reaction was quenched by addition of water (8 ml). After 30 min the 
products were concentrated under reduced pressure then the residue was dissolved in 
dichloromethane (80 ml) and extracted with saturated aqueous sodium hydrogen carbonate 
(40 ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (4x20 ml). The combined organic layers were extracted with 
triethylammonium phosphate buffer (40 ml, 0.5 M, pH 7.0). The aqueous layer was back 
extracted with dichloromethane (20 ml). The combined organic layers were dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by short column 
chromatography on silica gel. The appropriate fractions which were eluted with 
dichloromethane-methanol (96:4 v/v) were combined and concentrated under reduced 
pressure to give the compound 66 as a withe froth (1.60 g, 92%). 
ESI-MS [M-H]
¯
 found 1019.4, C48H45ClN4O10P required 1019.40 
δH[(CD3)2SO]: 11.28 (1 H, s), 8.24 (1 H, d, J = 7.8), 8.02-7.99 (2 H, m), 7.66-7.61 ( 1 H, m), 
7.54-7.49 (2 H, m), 7.47-7.38 (2 H, m), 7.37-7.22 (15 H, m), 6.94 (2 H, d, J = 9.0), 6.12 (1 H, 
d, J = 6.0), 4.62-4.54 (2 H, m), 4.28-4.27 (1 H, m), 4.02 (1 H, dd, J = 5.4 and 10.5 ), 2.96 (1 
H, d, J = 7.8), 3.10-2.80 (14 H, m), 1.93-1.76 (4 H, m), 1.66-1.78 (1 H, m), 1.10-1.10 (23 H, 
m), 1.01 (3 H, t, J = 15.0). 
δP[(CD3)2SO]: 0.09 (d, J = 56.6). 
Rf : 0.55 (system B) 
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4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-3ʹ-O-levulinylcytidine 67 
 
 
4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-O-[9-(p-tolyl)xanthen-9-yl] 
cytidine 65 (2.30 g, 2.69 mmol) was evaporated with dry pyridine (2x5 ml), and then 
dissolved in dry pyridine (30 ml). Levunilic anhydride (1.15 g, 5.37 mmol) was added 
followed by addition of N,N-dimethylaminopyridine (0.026 g, 3.22 mmol) and triethylamine 
(0.75 ml, 7.5 mmol). After 30 minutes the products were partitioned between 
dichloromethane (60 ml) and saturated sodium hydrogen carbonate solution (40 ml). The 
organic layer was separated and the aqueous layer was back extracted with dichloromethane 
(2x10 ml). The combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. After the residue was co-evaporated with toluene (2x10 ml), it was dissolved in 
dichloromethane followed by addition of pyrrole (1.8 ml, 26.8 mmol) and trifluoroacetic acid 
(1.24 ml, 10.7 mmol). After 30 second the reaction was quenched by addition of N-
methylmorpholine (2.30 ml, 22.8 mmol). The products were partitioned between 
dichloromethane (60 ml) and saturated sodium hydrogen carbonate solution (40 ml). The 
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organic layer was separated and the aqueous layer was back extracted with dichloromethane 
(2x10 ml). The combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. The residue was purified by short column chromatography. The appropriate 
fractions, which were eluted with dichloromethane-methanol (98:2 v/v) were combined and 
concentrated under reduced pressure to give the compound 67 as a colorless froth (1.50 g, 
82%). 
ESI-MS [M-H]
¯
 found 682.2, C34H39ClN4O9 required 682.24 
δH[(CD3)2SO]: 11.35 (1 H, s), 8.42 (1 H, d, J = 7.2), 7.96 (2 H, d, J = 7.5), 7.64 (1 H, t, J = 
14.7), 7.52 (2 H, t, J = 14.7), 7.40 (1 H, s), 7.15 (2 H, d, J = 8.7), 6.87 (2 H, d, J = 9.0), 6.18 
(1 H, d, J = 7.8), 5.50 (1 H, s), 5.16 (1 H, d, J = 4.8), 4.60-4.65 (1 H, m), 4.08 (1 H, s), 3.67 
(2 H, s), 3.13-3.18 (3 H, m), 2.99-3.03 (1 H, m), 2.85-2.88 (1 H, m), 2.71-2.69 (3 H, m), 2.58-
2.54 ( 2 H, m),  
1.79-1.81 (4 H, m), 1.55-1.62 (1 H, m), 0.88 (5 H, t, J = 13.8). 
Rf : 0.54 (system C). 
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Px-Cʹʹp(sʹ)Cʹʹ-Lev* 68 
 
 
4-N-Benzoyl-2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-5ʹ-O-[9-(p-tolyl)xanthen-9-yl] 
cytidine 3ʹ-H phosphonate, triethylammonium salt 66 (1.50 g, 1.49 mmol) and 4-N-benzoyl-
2ʹ-O-[(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-3ʹ-O-levulinylcytidine 67 (0.70 g, 1.02 
mmol) were co-evaporated with dry pyridine (2x5 ml) and then dissolved in dry pyridine (20 
ml), while the temperature kept at 0°C (ice bath) pivaloyl chloride (0.20 ml, 1.73 mmol) was 
added. After 5 min 2-phenylsulfanyl-1H-isoindole-1,3(1H)-dione (0.70 g, 1.83 mmol) was 
added. The reaction mixture was stirred for 30 min at room temperature and the reaction was 
quenched by addition of water (0.2 ml). The products were partitioned between 
dichloromethane (60 ml) and saturated sodium hydrogen carbonate solution (40 ml). The 
organic layer was separated and the aqueous layer was back extracted with dichloromethane 
(2x10 ml). The combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. The product was purified by short column chromatography on silica gel. The 
appropriate fractions which were eluted with dichloromethane-methanol (98:2 v/v) were 
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combined and concentrated under reduced pressure to give the compound 68 as a colorless 
froth (1.30 g, 75%). 
ESI-MS [M-H]
¯
 found 1690.1, C89H89Cl2N8O18 required 1690.50 
δH[(CD3)2SO]: 11.35 (1 H, s), 7.99 (2 H, d, J = 6.8), 7.61-7.64 (1 H, m), 7.51 (3 H, t, J = 
15.9), 7.45-7.33 ( 3 H, m), 7.32- 7.25 (3 H, m), 7.09-7.17 (6 H, m), 6.85-6.95 (2 H, m), 6.04-
6.13 (1 H, m), 4.97-4.74 (1 H, m), 4.40 (1 H, s), 4.14-4.19 (1 H, m), 3.16 (3 H, d, J = 5.1), 
3.04-2.89 (1 H, m), 2.88-2.77 (1 H, m), 2.65-2.71 (1 H, m), 2.24 (1 H, s), 2.08 (2 H, t, J = 
12.0), 1.77-1.86 (3 H, m,), 1.22 (1 H, s), 1.02-0.82 (3 H, m). 
Rf : 0.52 (system C). 
δP[CD3)2SO]: 22.83.  
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HO-Cʹʹp(sʹ)Cʹʹp(H) Chemical Formula 71 
 
 
Px-Cʹʹp(sʹ)Cʹʹ-Lev 68 (0.70 g, 0.41 mmol) was dissolved in pyridine (5.0 ml), followed by 
addition of a mixture of hydrazine monohydrate (0.12 ml, 4.5 mmol), acetic acid (2.6 ml), 
water (0.35 ml) and pyridine (5.0 ml). After 15 min the reaction was quenched by addition of 
pentan-2,4-dione (0.8 ml). The products were concentrated under reduced pressure after 10 
min. The residue was dissolved in dichloromethane (15.0 ml) and extracted with saturated 
aqueous sodium hydrogen carbonate (8.0 ml). The layers were separated and the aqueous 
layer was back extracted with dichloromethane (4x5 ml). The combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure. To the residue were added p-tolyl 
H-phosphonate  (0.30 g, 1.23 mmol), triethylamine (0.3 ml, 2.9 mmol) and methanol (1.0 ml) 
and the mixture were evaporated under reduced pressure. The residue was evaporated with 
dry pyridine (2x5 ml) and then dissolved in dry pyridine (5.0 ml) followed by addition of 
pivaloyl chloride (0.15 ml, 1.23 mmol) over a period of 5 min while temperature was kept at 
0°C (ice bath). The reaction mixture was stirred for 30 min at the same temperature, and the 
reaction was quenched by addition of water (0.5 ml). The products were concentrated under 
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reduced pressure. The residue was dissolved in dichloromethane (20.0 ml) and extracted with 
saturated aqueous sodium hydrogen carbonate (10.0 ml). The layers were separated and the 
aqueous layer was back extracted with dichloromethane (2x5 ml). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. The residue was then 
co-evaporated with dry toluene (3x5 ml) and then dissolved in dry dichloromethane (10.0 ml) 
followed by addition of distilled pyrrole (0.27 ml, 4.13 mmol) and distilled trifluoroacetic 
acid (0.42 ml, 3.71 mmol). After 30 sec the reaction was quenched by addition of N-
methylmorpholine (0.43 ml, 3.71 mmol). The products were extracted with saturated aqueous 
sodium hydrogen carbonate (10.0 ml). The layers were separated and the aqueous layer was 
back extracted with dichloromethane (2x5 ml). The combined organic layer was extracted 
with triethylammonium phosphate buffer (10.0 ml, 0.5 M, pH 7.0) and aqueous layer was 
back extracted with dichloromethane (2x5 ml). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (96:4 v/v), were concentrated with a rotary evaporator to give the 
compound 71 as a white glass (0.55 g, 89%). 
ESI-MS [M-H]
¯
 found 1501.5, C65H71Cl2N8O15 required 1501.48 
δH[(CD3)2SO]: 11.35 (1 H, s), 8.01 (2 H, d, J = 8.4), 7.62 (1 H, d, J = 6.9), 7.52 (3 H, d, J = 
7.8), 7.23 ( 2 H, d, J = 9.3), 7.20-7.07 ( 3 H, m), 6.88-6.92 (2 H), 6.23- 6.03 (1 H, m), 4.64-
4.68 (1 H, m), 3.06-3.08 (12 H, m), 2.98-2.86 ( 1 H, m), 2.85-2.76 (1 H, m), 1.96- 1.68 (3H, 
m), 2.25 (2 H, s), 1.17 (16 H, t, J = 6.0), 0.88-0.89 (4 H, m, J = 3.2). 
Rf : 0.87 (system A) 
δP[CD3)2SO]: 2.78, and 23.15. 
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Preparation of fully protected c-di-CMP 72 
 
 
HO-C’’p(s’’)C’’pH 71 (100 mg, 0.07 mmol) was co-evaporated with dry toluene (2x3 ml) 
and then dissolved in dry dichloromethane (5.0 ml). This solution was then added dropwise 
over a period of 20 min at -40
º 
C (dry ice-acetone bath) to a solution of diphenyl 
chlorophosphate (0.25 ml, 1.22 mmol) in dry pyridine (5.0 ml). The reaction mixture was 
stirred for 20 min followed by addition of 1-phenylsulfanyl-pyrrolidine 2,5-dione (0.22 g, 
1.34 mmol). The reaction mixture was then allowed to warm up to room temperature over 30 
min. After 5 min water (3.0 ml) was added, the products were extracted with saturated 
aqueous sodium hydrogen carbonate (10.0 ml). The layers were separated and the aqueous 
layer was back extracted with dichloromethane (2x5 ml). The combined organic layers were 
dried (MgSO4) and concentrated with a rotary evaporator. The residue was purified by 
column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane- methanol (97:3 v/v), were concentrated with a rotary evaporator to give the 
compound 72 as a white glass (65 mg, 80%). 
ESI-MS [M-H]
¯
 found 1504.1, C72H76Cl2N8O16P2S2 required 1504.36 
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δH[(CD3)2SO]:  11.41 (1 H, s), 8.42 (1 H, d, J = 9.0), 8.03 (3 H, d, J = 7.8), 7.84 (1 H, d, J = 
7.8), 7.69-7.60 (2 H, m), 7.58-7.49 (6 H, m), 7.46 (2 H, d, J = 9.0), 7.40-7.30 (3 H, m), 7.28-
7.20 (6 H, m), 7.19-7.12 (4 H, m), 6.95-6.83 (5 H, mm), 6.05-5.92 (1 H, m), 5.91-5.80  (1 H, 
m), 5.11-4.96 (3 H, m), 4.73-4.57 ( 2 H, m), 4.19-4.05 (1 H, m), 3.98 (2 H, t, J = 14.7), 3.80-
3.67 (2 H, m), 3.58-3.49 (2 H, m), 3.25 (1 H, s), 3.20-3.04 (3 H, m), 3.05-2.90 (3 H, m), 2.89-
2.71 (3 H, m), 2.37-2.79 (6 H, m), 2.26-2.18 (3 H, m), 2.00 (2 H, s), 1.89-1.77 (7 H, m), 1.62-
1.44 ( 5 H, m), 1.39-1.29 (4 H, m), 1.28-1.11 (12 H, m), 1.05-0.90 (9 H, m), 0.90-0.78 (5 H, 
m). 
Rf : 0.56 (system C).  
δP[CD3)2SO]:  25.57. 
 
Preparation of partially protected c-di-CMP 73 
 
 
 
Fully-protected c-di-CMP 72 (57 mg, 0.37 mmol) was evaporated with dry toluene (2x2 ml) 
and the residue was dissolved in dry acetonitrile (2 ml). 2-Nitrobenzaldoxime (0.88 mg, 0.53 
mmol) followed by N,N,Nʹ,Nʹ- tetramethylguanidine (61 μl, 0.49 mmol) were added. The 
reactants were stirred at room temperature for 16 hours and were then concentrated under 
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reduced pressure. To the residue was added concentrated aqueous ammonia (33%, d 0.88, 2.0 
ml) and the mixture was heated at 55°C for 15 hours. After the products had been cooled, 
they were concentrated to dryness followed by co-evaporation with ethanol (2x2 ml) under 
reduced pressure. The residue was dissolved in methanol (1 ml) and precipitated with diethyl 
ether (30 ml). The precipitate was collected by centrifugation. This precipitation-
centrifugation process was repeated for one more time and the solid residue was dried in 
vacuo to give 2ʹ-O-Cpep c-di-CMP as colorless solid (32 mg, 89%). 
ESI-MS [M-H]
¯
 found 1083.0, C44H54Cl2N8O16P2
¯
 required 1082.25 
δH[(CD3)2SO]:  7.91 (1 H, d, J = 9.0), 7.53-7.40 (3 H, m), 7.27 (3 H, d, J = 9.0), 7.04 (2 H, d, 
J = 9.0), 5.97 (2 H, d, J = 9.0), 4.56 (1 H, s), 4.37-4.30 (1 H, m), 4.25 (1 H, d, J = 15.1), 3.97 
(1 H, d, J = 13.5), 3.67 (1 H, t, J = 15.9), 3.57-3.44 (6 H, m), 3.39-3.30 (1 H, m), 3.06-2.97 (2 
H, m), 2.96-2.91 (12 H, m), 2.36 (1 H, s), 2.09-2.01 (4 H, m), 1.93 (1 H, s), 1.13-1.03 (1o H, 
m). 
Rf : 0.64 (system C). 
δP[CD3)2SO]: 0.03. 
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Preparation of fully deprotected c-di-CMP 74 
 
 
 
2ʹ-O-Cpep protected c-di-CMP 73 (30 mg, 0.24 mmol) was dissolved in N,N-
dimethylacetamide (1.8 ml) followed by addition of triethylammonium formate buffer (0.5 
M, pH 2.52, 1.2 ml, prepared with sterile water). The reactants were then sealed and heated at 
40°C. After 5 hours, the products were cooled, and the pH was adjusted to 7.0 with 
triethylamine. The products were then extracted with chloroform (4x2.0 ml). The organic 
layers were discarded. The aqueous layer was evaporated under reduced pressure at room 
temperature to a volume of 0.2 ml. To the residue was added n-butanol (2.0 ml). The mixture 
was vortexed vigorously and then chilled at -78°C (dry ice–acetone bath) for 10 minutes. 
Then it was centrifuged for 10 min. The supernatant was discarded and the pellet was re-
dissolved in sterile water (0.2 ml). The above precipitation–centrifugation process was 
repeated two more times. The final pellet was then dried in vacuo.  
This material was dissolved in sterile water (1.0 ml) and passed through an Amberlite (IR120, 
Na
+
 form) cation-exchange column (0.5×2.0 cm). The fractions which contained 
oligonucleotide were pooled and freeze-dried to give the fully unblocked c-di-CMP as a 
colorless froth (18.0 mg, 94%). 
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ESI-MS [M-H]
¯
 found 608.0, C18H22N6O14P22
-
  required 608.06 
δH[CD3)2SO]: 8.05 (1 H, d, J = 7.8), 5.99 (1 H, d, J = 7.5), 5.71 (1 H, s), 3.95 (1 H, d, J = 
14.4), 4.50-4.40 (2 H, m), 4.39-4.27 (4 H, m), 3.95 (1 H, d, J = 12.9).  
δP[CD3)2SO]: 1.17. 
 
6-Bromo-1-hexanol 85 
 
 
 
A literature procedure was followed for the preparation of this compound.ref 1,6-Hexandiol 
83 (20.0 g, 0.169  mol) and hydrobromic acid (48% in water, 60.0 ml) were added to toluene 
(200.0 ml) and the mixture was heated under reflux with vigorous stirring for 2 h. after the 
reaction mixture was cooled to 0ºC (ice-water bath), the organic layer was separated and 
washed successively with saturated aqueous sodium hydrogen carbonate (2x50 ml) and water 
(70.0 ml), and then concentrated under reduced pressure to give the compound 85 as a 
colorless liquid (30.10 g, 98%). 
1
H NMR data are in agreement with literature values.
98
 
δH[CD3)2SO]:  4.02 (1 H, s), 3.52 (2 H, t, J = 18.0), 3.37 (2 H, t, J = 12.1), 2.51 (1 H, s), 1.85-
1.75 (2 H, m), 1.49-1.23 (5 H, m). 
1-Benzyloxy-6-bromohexane  86 
 
 
Sodium hydride (883 mg, 22.1 mmol) was suspended in dry tetrahydrofuran (20.0 ml) 
followed by dropwise addition of a solution of 6-bromo-1-hexanol 85 (4.01 g, 22.1 mmol) in 
84 
 
tetrahydrofuran (5.0 ml) while temperature was kept at 0°C (ice-water bath). After 30 min 
solution of benzyl bromide (3.78 g, 22.1 mmol) in tetrahydrofuran (5.0 ml) was added at the 
same temperature. After 24 h the products were concentrated under reduced pressure. The 
residue was dissolved in ethylacetate (200 ml) and extracted with water (40 ml) and brine (40 
ml). The organic layer was dried (MgSO4) and concentrated by a rotary evaporator. 
Distillation performed to get the desired product at 120°C (5.72g, 96%)(1.5 × 10
-3 torr
).
1
H 
NMR data are in agreement with literature values.
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δH[CD3)2SO]:  7.38-7.23 (5 H, m), 4.44 (2 H, s), 3.50 (2 H, t, J = 12.2), 3.41 (2 H, t, J = 
12.3), 1.84-1.73 (2 H, m), 1.59-1.48 (2 H, m), 1.45-1.27 (4 H, m). 
 
2ʹ-O-(6-Benzoxylhexyl)-2,6-diaminopurine riboside  88 
 
 
2,6- Diaminopurine riboside 87 (10.0 g, 35.4 mmol) ) was dried at 80°C in vacuo for 5 h and 
then suspended in N,N-dimethylformamide (100.0 ml) followed by addition of sodium 
hydride (1.60 g, 39.0 mmol). The mixture was stirred for 1 h and then 1-benzyloxy-6-
bromohexane 85 (7.03 ml, 35.4 mmol) was added dropwise over a period of 5 min while 
temperature was kept at 0°C (ice-water bath). After 48 h, the reaction was quenched by 
addition of water (5.0 ml). The products were concentrated under reduced pressure and the 
residue was purified by column chromatography on silica gel. The appropriate fractions, 
85 
 
which were eluted with dichloromethane-methanol (98.5:1.5 v/v), were concentrated by 
rotary evaporator to give the compound 88 as a white glass (5.45 g, 32%). 
ESI-MS [M-H]
¯
 found 472.7, C23H32N6O5 required 472.24 
δH[CD3)2SO]: 7.95 (1 H, s), 7.25-7.35 (5 H, m), 6.78 (2 H, s), 5.79 (1 H, d, J = 6.9), 5.73 (2 
H, s), 5.48-5.44 (1 H, m), 5.08 (1 H, d, J = 5.7), 4.42-4.35 (3 H, m), 4.26-4.20 (1 H, m), 3.93-
3.92 (1 H, m), 3.64-3.59 (1 H, m), 3.56-3.49 (2 H, m), 1.45-1.38 (4 H, m), 1.33-1.21 (4 H, 
m). 
δC[CD3)2SO]: 25.6, 29.9, 29.5, 62.2, 69.7, 70.0, 72.2, 81.1, 85.8, 86.8, 113.9, 127.7, 127.8, 
128.6, 136.8, 139.2, 151.8, 156.5, 160.3. 
Rf : 0.57 (system B). 
2ʹ-O-(6-Benzyloxyhexyl)-3ʹ,5ʹ-O-(1,1,3,3-tetraisopropyldisiloxyl)-2,6-diaminopurine-D 
riboside 89 
 
 
 
2ʹ-O-(6-Benzyloxyhexyl)-2,6-diaminopurine riboside 88 (3.00 g, 4.19 mmol) was co-
evaporated with dry pyridine (2x10 ml) then dissolved in anhydrous pyridine (30.0 ml), 
followed by addition of 1,1-dichloro-1,1,3,3-tetraisopropyldisiloxane (1.07 ml, 5.02 mmol) 
while the temperature was kept at 0°C (ice-water bath). After 5 h the products were 
concentrated under reduced pressure and then partitioned between dichloromethane (60 ml) 
86 
 
and saturated aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the 
aqueous layer was back-extracted with dichloromethane (3x10 ml). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel. The appropriate fractions, which 
were eluted with dichloromethane-methanol (98:2  v/v) were combined and concentrated 
under reduced pressure to give the compound 89 as a colorless froth (4.50 g, 90%). 
ESI-MS [M-H]
¯
 found 714.5, C35H58N6O6Si2 required 714.39. 
δH[CD3)2SO]:  7.76 (1 H, s), 7.37-7.21 (5 H, m), 6.79 (2 H, s), 5.75 (3 H, d, J = 7.8),4.52-4.53 
(1 H, m), 4.42 (2 H, s), 4.25-4.30 (1 H, m),4.20-4.01 (1 H, m), 4.02-4.14 (2 H, m), 3.73-3.82 
(1 H, m), 3.70-3.60 (1 H, m), 3.39-3.37 (1 H, m),  1.53-1.51 (4 H, m), 1.32-1.23 (4 H, m), 
1.04-1.00 (29 H, m). 
δC[(CD3)2SO]: 12.7, 12.8, 13.2, 17.2, 17.3, 17.4, 17.6, 17.7, 17.8, 25.9, 26.0, 29.6, 29.8, 60.8, 
70.0, 70.3, 70.9, 72.2, 81.2, 81.3, 87.0, 127.8, 128.6, 139.2,154.0, 156.4, 176.2,. 
Rf : 0.38 (system B). 
 
2ʹ-O-(6-Benzyloxyhexyl)-2(N-isobutyryl)-6-riboside 90 
 
 
2ʹ-O-(6-Benzyloxyhexyl)-3ʹ,5ʹ–O-(1,1,3,3-tetraisopropyldisiloxyl)-2,6-diaminopurine-D 
ribosede 89    (3.00 g, 4.19 mmol) was dissolved in dry pyridine (30.0 ml) followed by 
addition of solution of isobutyric chloride (1.0 ml, 4.61 mmol) in dry dichloromethane (3.0 
87 
 
ml) dropwise at room temperature. The reaction mixture was stirred for 1 h at the same 
temperature and then (check the TLC) it was quenched by addition of ethanol (5.0 ml). The 
products were concentrated under reduced pressure. The residue was dissolved in 
dichloromethane (30.0 ml) and extracted with saturated aqueous sodium hydrogen carbonate 
(15.0 ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (2x10 ml). The combined organic layers were dried by (MgSO4) and 
concentrated with a rotary evaporator. 
To the residue was added methanol (5.0 ml) and concentrated aqueous ammonia (33%, d 
0.88, 10.0 ml) and the mixture was heated at 55ºC for 20  h. After the products had been 
cooled, they were concentrated to dryness. The residue was dissolved in acetonitrile (10.0 ml) 
followed by addition of a tetraethylammonium fluoride solution in acetonitrile (10.0 ml, 1.0 
M, pH 8.0). The reaction mixture was stirred for 30 min and concentrated to dryness under 
reduced pressure. The residue was purified by column chromatography on silica gel. The 
appropriate fractions, which were eluted with dichloromethane-methanol (96:4 v/v), were 
concentrated under reduced pressure to give the compound 90 as a white glass (0.50 g, 65% 
for three steps). 
ESI-MS [M-H]
 ¯
 found 54.2, C27H38N6O6 required 542.28 
δH[CD3)2SO]:  9.83 (1 H, s), 8.27 (1 H, s), 7.36-7.31 (2 H, m), 7.30-7.20 (5 H, m), 5.92 (1 H, 
d, J = 6.0), 5.13 ( 1 H, d, J = 4.8), 5.05 (1 H, t, J = 11.4), 4.46 (1 H, t, J = 11.4), 4.40 (2 H, s), 
4.28-4.25 (1 H, m), 3.93-3.91 (1 H, m), 3.66-3.61 (1 H, m), 3.58-3.51 (2 H, m), 3.38-3.36 (1 
H, m),  2.84 (1 H, s), 1.45-138 (4 H, m), 1.23-1.11 (5 H, m), 1.06-1.03 (6 H, m), 0.93-0.78 (1 
H, m). 
δC[CD3)2SO]: 19.8, 25.6, 25.9, 29.5, 29.5, 31.0, 31.1, 31.2, 31.3, 34.5, 55.4, 61.8, 69.3, 69.9, 
70.0, 72.2, 79.6, 81.1, 85.4, 86.5, 116.7, 127.7, 127.8, 128.6, 139.1, 139.2, 150.7, 153.3, 
156.6, 175.4, 207.0. 
Rf : 0.69 (system B). 
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2ʹ-O-(6-Benzyloxyhexyl)-N2-isobutyryl-guanosine 91 
 
 
2ʹ-O-(6-Benzoxyhexyl)-N2-isobutiryl-6-aminopurine riboside 90 (1.00 g, 1.84 mmol) was 
dissolved in N,N-dimethylacetamide (15.0 ml) followed by addition of glacial acetic acid 
(28.0 ml) and water (14.0 ml). A solution of sodium nitrite (1.39 g, 20.3 mmol) in water (3.0 
ml) was then added dropwise while the temperature was kept at 4°C. After 24 h another 
portion of sodium nitrite (1.39 g, 20.28 mmol) in water (3.0 ml) was added. The reaction 
mixture was stirred at 4°C for 5 days with addition of the same portion of sodium nitrite in 
water on a daily basis (check TLC). The solvents were evaporated in vacuo to dryness. The 
residue was dissolved in dichloromethane (30.0 ml) and extracted with saturated aqueous 
sodium hydrogen carbonate (15.0 ml). The layers were separated and the aqueous layer was 
back extracted with dichloromethane (2x10 ml). The combined organic layers were dried 
(MgSO4) and then concentrated with a rotary evaporator. The appropriate fractions, which 
were eluted with dichloromethane-methanol (96:4 v/v), were concentrated under reduced 
pressure to give the compound 91 as a white glass (0.75 g, 75%). 
ESI-MS [M-H]
 ¯ 
found 544.1, C27H37N5O7 required 544.27 
δH[(CD3)2SO]:  12.10 (1 H, s), 11.70 (1 H, s), 8.30 (1 H, s), 7.35-7.24 (6 H, m), 5.89 (1 H, d, 
J = 6.8), 5.18 (1 H, d, J = 4.4), 5.09 (1 H, s), 4.47-4.24 (1 H, m), 4.39 (2 H, s), 4.34-4.31 (1 
H, m), 4.28-4.24 (1 H, m), 3.95-3.93 (1 H, m), 3.65-3.58 (2 H, m), 3.58-3.52 (2 H, m), 3.34-
89 
 
3.30 (3 H, m), 2.78-2.72 (1 H, m), 1.44-1.37 (4 H, m), 1.20-1.14 (4 H, m), 1.11 (4 H, t, J = 
13.6). 
Rf : 0.66 (system B). 
δC[CD3)2SO]: 19.3, 25.6, 25.9, 29.4, 29.6, 31.1, 35.2, 61.7, 69.3, 69.9, 70.1, 72.2, 81.8, 84.9, 
86.8, 120.5, 127.7, 127.8, 128.6, 137.9, 139.1, 148.7, 149.5. 
 
2ʹ-O-(6-Benzyloxyhexyl)-3ʹ,5ʹ–O-(1,1,3,3-tetraisopropyldisiloxyl)-N2-isobutyryl-
guanosine 92 
 
 
 
 
 
2ʹ-O-(6-Benzyloxyhexyl)-N2-isobutyryl-guanosine 91 (1.50 g, 2.76 mmol) was co-evaporated 
with dry pyridine (2x10 ml) and then it was dissolved in dry pyridine (20.0 ml), followed by 
addition of 1,1-dichloro-1,1,3,3-tetraisopropyldisiloxane (0.95 ml, 3.03 mmol) while the 
temperature was kept at 0°C (ice-water bath). After 5 h the products were concentrated under 
reduced pressure and then partitioned between dichloromethane (60 ml) and saturated 
aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the aqueous 
layer was back-extracted with dichloromethane (3x10 ml). The combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure. The residue was fractionated by 
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short column chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (98:2  v/v) were combined and concentrated under reduced 
pressure to give the compound 92 as a colorless froth (2.60 g, 88.0%). 
 
ESI-MS [M-H]
¯
 found 771.2,  C38H61N5O8Si2 required 771.40  
δH[CD3)2SO]:  12.12 (1 H, s), 11.62 (1 H, s), 8.03 (1 H, s), 7.45-7.20 (5 H, m), 5.82 (1 H, s), 
4.52-4.38 (3 H, m), 4.24-4.23 (1 H, m), 4.15-3.91 (3 H, m), 3.79-3.76 (1 H, m), 3.67-3.62 (1 
H, 
m), 2.89-2.70 (1 H, m), 1.60-1.49 (4 H, m), 1.32-1.30 (5 H, m), 1.05-0.95 (30 H, m). 
δC[CD3)2SO]: 12.5, 12.7, 12.8, 13.2, 13.3, 17.2, 17.3, 17.6, 17.6, 17.6, 17.8, 19.3, 25.8, 25.9, 
29.6, 29.8, 35.2, 60.7, 70.0, 70.2, 71.0, 72.2, 81.3, 81.8, 87.0, 120.7, 127.7, 128.6, 136.7, 
139.1, 148.4, 148.7, 155.2, 180.6. 
Rf : 0.35 (system B). 
2
׳
-O-(6-Hydroxyhexyl)-3ʹ,5ʹ–O-(1,1,3,3-tetraisopropyldisiloxyl)-N2-isobutyryl-guanosine 
93 
 
 
 
2ʹ-O-(6-Benzyloxyhexyl)-3ʹ,5ʹ–O-(1,1,3,3-tetraisopropyldisiloxyl)-N2-isobutiryl-guanosine 
92 (0.30 g, 0.389 mmol) was dissolved in regular tetrahydrofuran (20.0 mL) and then it was 
followed by addition of excess amount of Pd/C (10%wt) (0.58 g, 0.389 mmol). The reaction 
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was shaken in a hydrogen atmosphere (50 psi) for 7 days. The reaction mixture was filtered 
through a bed of Celite. The filtrate was concentrated under reduced pressure. The residue 
was fractionated by short column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (98:2  v/v) were combined and 
concentrated under reduced pressure to give the compound 93 as a colorless froth (0.24 g, 
88%). 
ESI-MS [M-H]
¯
 found 695.0,  C32H57N5O8Si2 required 695.37 
δH[CD3)2SO]:  12.28 (1 H, s), 11.62 (1 H, s), 8.02 (1 H, s), 5.83 (1 H, s), 4.49 (1 H, d, J = 
4.8), 4.48 (1 H, s), 4.25 (1 H, d, J = 4.8), 4.10 (1 H, d, J = 13.2), 4.02 (1 H, d, J = 8.4), 3.95 
(1 H, d, J = 12), 3.79-3.76 (1 H, m), 3.66-3.63 (1 H, m), 2.79-2.76 (1 H, m), 1.54-1.50 (3 H, 
m), 1.40-1.23  
(9 H, m), 1.12 (8 H, d, J = 6.6), 1.09-0.9 (24 H, m). 
δC[CD3)2SO]: 13.6, 14.2, 17.3, 17.5, 17.6, 19.2, 21.4, 22.5, 22.8, 23.7, 25.8, 26.0, 29.5, 30.0, 
30.8, 35.1, 61.1, 67.7, 70.2, 71.2, 72.7, 81.4, 81.7, 87.1, 120.8, 125.3, 127.6, 128.4, 128.5, 
128.8, 129.0, 129.6, 131.8, 132.2, 136.6, 139.5, 148.4, 148.7, 151.9, 155.2, 167.3, 174.8, 
180.6. 
Rf : 0.30 (system B). 
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1,1,3,3-Tetraisopropyldisiloxane 97 
 
 
To a suspension of magnesium turnings (34.6 g, 1.43 mol), iodine (0.1 g) in dry diethylether 
(500 ml) was added dropwise 2-bromopropane (130 ml, 1.38 mol) at such a rate that a gentle 
reflux was maintained. After the addition was complete, the reactants were cooled (ice-salt 
bath). A solution of trichlorosilane (50 ml, 0.493 mol) in dry diethylether (400 ml) was added 
dropwise over a period of 2 h, while the temperature was kept below 15°C. The reaction 
mixture was heated under reflux for 6 h and then cooled (ice-salt bath). To this cooled 
mixture was added hydrochloric acid (10% w/v, 660 ml) dropwise while the temperature did 
not exceed 15°C. 
After the addition was complete, stirring was continued for 30 min. The layers were separated 
and the aqueous layer was back-extracted with diethyl ether (4x100 ml). The combined 
organic layers were further washed with water (2x100 ml), dried (MgSO4) and concentrated 
under reduced pressure. Distillation of the residue under reduced pressure afforded the 
compound 97 as a colorless liquid (53.30 g, 87%, 118-120°C/28 mmHg).
 1
H NMR data are in 
agreement with literature values.
94
 
δH[CD3)2SO]: 4.43 (2H, s), 1.10-1.06 (28H, m). 
δC[CD3)2SO]: 17.15, 13.26. 
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1,1-Dichloro-1,1,3,3-tetraisopropyldisiloxane 98 
 
 
To a solution of 1,1,3,3-tetraisopropyldisiloxane (80.0 g, 0.324 mol) in dichloromethane (500 
ml) cooled at 0ºC (ice-salt bath) was added dropwise a saturated solution of chlorine in 
dichloromethane (600 ml) until a yellow color persisted. The products were then evaporated 
under reduced pressure and the residue was distilled under reduced pressure to give 
compound 98 as a colorless liquid (88 g, 86%, 92-96°C/0.7 mmHg).
 1
H NMR data are in 
agreement with literature values.
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δH[CD3)2SO]: 1.53-1.10 (28H, m). 
δC[CD3)2SO]: 16.54, 15.44. 
9-Phenylxanthen-9-ol 99 
 
A literature procedure was followed for the preparation of this compound.
95
 Magnesium 
turnings (2.43 g, 0.10 mol) were suspended in dry diethyl ether (30.0 ml) followed by 
addition of a small crystal of iodine (15 mg). Then a solution of bromobenzene (15.70 g, 
10.46 ml, 0.10 mol) in dry diethyl ether (50.0 ml) was added dropwise over a period of 1 h. 
the reactants were then heated gently under reflux until the magnesium turnings disappeared. 
Then xanthen-9-one (9.81 g, 50 mmol) was added, followed by addition of dry diethyl ether 
94 
 
(50.0 ml). After the reactants had been heated under reflux for 2.5 h. they were allowed cool 
to room temperature and the precipitate was collected by filtration, followed by washing with 
diethyl ether (2x20 ml). The filter cake was suspended in a mixture of water (200 ml) and ice 
(200 g). Concentrated hydrochloric acid (37% w/v, 40 ml) was added under vigorous stirring. 
After 30 min, the products were filtered and washed with water until the washings were 
neutral. The solid product was air-dried to give a pale yellow solid (12.5 g, 86%) which was 
recrystallized from ethanol to give 9-phenyl-xanthen-9-ol as colorless crystals (8.20 g).
 1
H 
NMR data are in agreement with literature values.
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δH[CD3)2SO]: 6.73 (br s, 1H),7.07 (t, 2H, J = 15), 7.11 (t, 1H, J = 13.2), 7.19–7.30 (m, 
8H),7.35 (d, 2H, J = 7.8). 
 
 
9-Chloro-9-phenylxanthene 100 
 
A literature procedure was followed for the preparation of this compound.
96
 9-Phenyl-
xanthen-9-ol 97 (4.47 g, 15.50 mmol) was evaporated with dry toluene (2x10 ml), and the 
residue was re-dissolved in anhydrous toluene (20.0 ml), followed by addition of acetyl 
chloride (13.0 ml, 0.183 mmol). After the reactants had been stirred for 16 h at room 
temperature under an atmosphere of argon, the products were evaporated under reduced 
pressure. The residue was co-evaporated with dry toluene (3x15 ml). The product was further 
dried in vacuo (oil pump) at 40ºC for 3 h to give the compound 100 as a pale yellow solid in 
95 
 
virtually quantitative yield (4.80 g). The product was used without further purification due to 
its sensitivity to moisture. 
2-Methylphenylsulfanyl-1H-isoindole-1,3(1H)-dione 101 
 
4-Methylbenzenethiol (15.19 g, 0.105 mol) and phthalimide (14.70 g, 0.10 mol) were 
dissolved in hot pyridine (40.0 ml) and acetonitrile (50.0 ml), and the stirred solution was 
cooled to room temperature. A solution of bromine (19.20 g, 6.19 ml, 0.12 mol) in 
acetonitrile (50.0 ml) was then added dropwise over 30 min. After a further period of 2h, 
methanol (200 ml) was added dropwise over 30 min. the products were cooled (ice-water 
bath) for 30 min, and then filtered to give compound 101 as pale yellow crystals (25.20 g, 
87%). Recrystallization of this material from methanol gave pale yellow crystals. 
1
H NMR 
data are in agreement with literature values.
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δH[CD3)2SO]:  7.40 (4H, m), 7.93 (2H, m), 7.98 (2H, m). 
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Appendix – Selected NMR Spectra 
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COSY-NMR of compound 92. 
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HSQC-NMR of compound 92. 
 
 
 
107 
 
 
  
 
1
H-NMR of compound 93. 
 
 
 
108 
 
 
 
 
COSY-NMR of compound 93. 
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D2O-exchange of compound 93. 
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HSQC-NMR of compound 89i (without TIPDS). 
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HMBC-NMR of compound 89i (without TIPDS) 
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COSY-NMR of compound 89i (without TIPDS). 
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H decoupling). 
 
 
 
 
 
 
 
 
 
